US 2012O074O14A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0074.014 A1 Tran et al. (43) Pub. Date: Mar. 29, 2012

(54) PRODUCT TYPICALLY BASED ON SALT OF Publication Classification PEROXYMONOSULFURIC ACID AND (51) Int. Cl SUITABLE FOR MEDICINAL USAGE, AND iBio/02 (2006.01) ASSOCATED PRODUCT FABRICATION B23P 19/00 (2006.01) A633/42 (2006.01) (75) Inventors: David Van Tran, San Jose, CA A6IR 9/14 (2006.01) (US); David Nguyen Tran, San CD7C 409/244 (2006.01) Jose, CA (US) A6II 3/327 (2006.01) s (52) U.S. Cl...... 206/438: 562/1; 514/578; 424/605; 424/400; 29/428 (73) Assignee: LuTran Industries, Inc. (57) ABSTRACT

21) Appl. No.: 13AO47,742 Products based on salt of peroxyperoxVmonosulfuric acid are suit (21) Appl. No 9 able for treating or/and preventing diseases and other debili tating medical conditions caused by bacterial, eukaryotic, (22) Filed: Mar. 14, 2011 prion, and viral pathogens and by non-pathogenic inflamma tion. The products may alternatively be based on inorganic Related U.S. Application Data halide and an oxidizing agent reactable in water with the inorganic halide to generate hypohalite ions. In addition, the (60) Provisional application No. 61/386,928, filed on Sep. products can be employed in other applications such as com 27, 2010. mercial and industrial applications.

5T. 2

.. 2. 1.4. J., Patent Application Publication Mar. 29, 2012 Sheet 1 of 2 US 2012/0074014 A1

cro Q-D

22

Fig. 2a Fig.2b Patent Application Publication Mar. 29, 2012 Sheet 2 of 2 US 2012/0074014 A1

90

92 US 2012/0074014 A1 Mar. 29, 2012

PRODUCT TYPCALLY BASED ON SALT OF the antibiotic. The adverse side effects of antibiotics are var PEROXYMONOSULFURIC ACID AND ied, and range from fever and nausea to major allergic reac SUITABLE FOR MEDICINAL USAGE, AND tions. ASSOCATED PRODUCT FABRICATION 0007 Fungi are eukaryotic pathogens similar to bacteria. Spores are metabolic byproducts of the life cycle of some CROSS-REFERENCE TO RELATED bacteria and fungi. Bacteria produce endospores located APPLICATION within the cytoplasm of the parental cells. Fungi produce a 0001. This claims priority to U.S. provisional patent appli variety of exospores. Spores are highly resistant to physical cation 61/386,928, filed 27 Sep. 2010, the contents of which and chemical agents. are incorporated by reference to the extent not repeated 0008. In medical parasitology, the term “parasite' means a herein. This is also related to U.S. patent application Ser. No. eukaryotic pathogenic organism. Hence, protozoan and meta 12/726,326, filed 17 Mar. 2009, the contents of which are Zoan infectious agents are classified as parasites whereas likewise incorporated by reference to the extent not repeated bacteria and viruses are not. Many parasites, such as proto herein. Zoa, fleas, and worms (helminths), carry disease or cause Sores or lesions which can become infected. FIELD OF USE 0009 Parasites live on or in the host from which it gets Some or all of its nourishment. Parasites are generally harmful 0002 This relates to products suitable for treating and to their hosts. The damage ranges widely from minor incon preventing debilitating conditions, including debilitating Venience to debilitating or fatal disease. An ectoparasite, Such medical conditions of humans. This also relates to manufac as a louse, tick, or leech, lives or feeds on the outer Surface of turing Such products. the host's body. Ectoparasites do not usually cause disease themselves. However, they are frequently a vector of disease. BACKGROUND OF THE INVENTION For example, tick parasites transmit organisms that can cause 0003 Inflammation is caused by tissue injury consisting disease. An endoparasite lives inside the body of its host. of complex reactions involving vascular and connective tis Endoparasites include organisms such as tapeworms, hook Sues. Tissue damage may result from microbial invasion, worms, and trypanosomes that live within the host's organs or auto-immune processes, tissue infection, allograft rejection, tissues as well as organisms such as sporozoans that invade and such hurtful and/or destructive external influences as the host's cells. heat, cold, radiant energy, electrical or chemical stimuli, and 0010 Aprion is an infectious agent generally made solely mechanical trauma. Tissue damage may involve any part of of protein and lacking nucleic acid. Prions are believed to the human body such as the joints (arthritis), bowels (inflam infect and propagate by refolding abnormally into a structure matory bowel disease), and lungs (pulmonary inflammation). which converts normal molecules of the protein into an abnor Whatever the cause or bodily site, inflammatory responses to mally structured form. Prions are generally quite resistant to tissue damage are quite similar, consisting of complicated denaturation by protease, heat, radiation, and formalin treat functional and cellular adjustments involving microcircula ments, although potency or infectivity may be reduced. tion, fluid shifts, and inflammatory cells (leukocytes). When 0011 A virus consists of a single nucleic acid, either deox tissue damage occurs, soluble chemical Substances are elabo yribonucleic acid (“DNA) or ribonucleic acid (“RNA”), and rated which initiate the inflammatory response. Inflammation a protein shell or coat Surrounding the nucleic acid. A com can be mild and self-limited or prolonged and seriously plete viral particle is called a virion. A virus uses the machin debilitating and chronic. ery of a host cell to reproduce and resides within the host cell. 0004 Numerous drugs have been developed to fight Consequently, viruses are difficult to eliminate without kill inflammation inhumans. The most prominent in current treat ing the host cells. It is believed that viral infections trigger ment are anti-inflammatory steroidal drugs, corticosteroids inflammatory responses which do not respond to anti-viral and non-steroidal anti-inflammatory drugs such as salicy drugs. Patients often ask for, and physicians often prescribe, lates. While these drugs are generally effective, they often antibiotics. While antibiotics destroy or prevent the growth of have adverse side effects. bacteria, antibiotics are useless in treating viral (and fungal) 0005. A pathogen is an infectious biological agent, some infections. Their misuse in treating viral diseases is one of the times referred to as a germ, which causes disease or illness to causes of antibiotic resistance to bacteria. its host. Many medical advances, such as vaccination, antibi (0012 Sporkenbach et al. (“Sporkenbach'), U.S. Pat. No. otics, and fungicides, have been used to safeguard against 4.404,191, discloses a viricide technique for inactivating infection by pathogens. Nevertheless, pathogens continue to viruses on animate and inanimate surfaces by contacting the threaten human life. Primary pathogens are bacteria, eukary surfaces with a salt of peroxymonosulfuric acid (H2SOs) otes, prions, and viruses. commonly known as Caro's acid. The peroxymonosulfuric 0006 Bacteria constitute one of the smallest organisms acid salt, applied from an aqueous solution, can be a salt of an containing all the material required for growth and self-rep alkali metal Such as potassium, Sodium, or lithium, a salt of an lication. Bacterial infections can be treated with antibiotics, alkaline earth metal Such as calcium or magnesium, or an classified as bacteriocidal if they kill bacteria and as bacte ammonium salt. Sporkenbach preferably employs KHSOs as riostatic if they prevent the bacteria from multiplying so the the peroxymonosulfuric acid salt. KHSOs is provided from human immune system can overcome them. There are many the mixed triple salt having the chemical formula 2KHSOs. types of antibiotics. Each type of antibiotic inhibits a process KHSOKSO, where KHSO is potassium hydrogen sulfate whose pathogen is different from that found in the host. The and KSO is potassium sulfate sometimes referred to as effectiveness of individual antibiotics varies with the location dipotassium sulfate. of the infection, the ability of the antibiotic to reach the site of (0013 KHSOs and 2KHSO.KHSOKSO, each have infection, and the ability of the bacteria to resist or inactivate multiple chemical names. Both KHSOs and 2KHSOs. US 2012/0074014 A1 Mar. 29, 2012

KHSOKSO are commonly referred to as “potassium phosphate, disodium phosphate, trisodium phosphate, tetra monopersulfate'. To avoid confusion, KHSOs is referred to Sodium pyrophosphate, monopotassium phosphate, dipotas herein as "potassium hydrogen peroxymonosulfate' or sim sium phosphate, tripotassium phosphate, and tetrapotassium ply “potassium peroxymonosulfate. 2KHSOs. KHSO. pyrophosphate. According to Auchincloss, one embodiment KSO. is referred to herein as “potassium monopersulfate of the biocide apparently consisted of 1.5 parts of sodium triple salt” or sometimes simply as "potassium monoperSul chloride, 50 parts of potassium monopersulfate triple salt, 10 fate’. parts of Sulfamic acid, 5 parts of malic or Succinic acid, 18.5 0014 Sporkenbach identifies poliovirus, coxsackie virus, parts of sodium hexametaphosphate and (possibly) other simian vacuolating virus 40 and adenovirus as being inacti alkali metal phosphate, and 15 parts of sodium dodecylben vated by potassium hydrogen peroxymonosulfate. Poliovirus Zene Sulfonate as the Surfactant. causes poliomyelitis. There are two forms of coxsackie Virus, 0019 Auchincloss reported generally good results in vari type A and type B. Coxsackie A virus causes hand, foot, and ously using its biocide to disinfect chickens, pigs, cows, and mouth disease, acute haemorrhagic conjunctivitis, herpan horses. Auchincloss also reported that chickens can drink the gina, and aseptic meningitis which includes viral meningitis. biocide (apparently without harm), the biocide is not a skin or Coxsackie B virus causes pleurodynia (Bornholm disease) eye irritant, it is possible to bathe in the biocide (likewise and can induce aseptic meningitis and diabetes mellitus type apparently without harm), and the biocide can be sprayed in 1. Simian vacuolating virus 40 can cause tumors and cancer. occupied rooms without causing discomfort. Adenovirus generally produces infections in the upper respi 0020 Potassium peroxymonosulfate triple salt used by ratory tract. Adenovirus infections often appear as gastroen Sporkenbach and Auchincloss is commercially available teritis, conjunctivitis, cystitis, and rash illness. Symptoms of from various sources including E.I. Dupont de Nemours and respiratory illness caused by adenovirus infection include Company under the trade name Oxone and United Initiators acute viral nasopharyngitis, pneumonia, croup, and bronchi under the trade name Caroat. Potassium hydrogen peroxy tis monosulfate, the principal component of potassium peroxy 0015 Sporkenbach discloses that its viricide technique monosulfate triple salt, is a strong oxidizing agent. For can disinfect inanimate Surfaces such as walls, floors and instance, potassium hydrogen peroxymonosulfate can con work Surfaces, hospital utensils, and Surgical and dental Vert halide ions into halogens, ferrous ions into ferric ions, instruments in industrial, domestic, and medical environ manganous ions into manganic ions, and hydrogen peroxide ments and animate Surfaces such as the skin of human and into oxygen. Potassium hydrogen peroxymonosulfate can non-human animals during presurgical preparation in human also initiate the free radical polymerization of vinyl mono and veterinary medicine. While Sporkenbach’s viricide tech mers such as vinyl acetate, ethyl acrylate, and acrylonitrile. In nique may prevent the diseases caused by the preceding addition to the uses mentioned above, potassium hydrogen viruses from being contracted, Sporkenbach's technique does peroxymonosulfate serves as a bleaching agent in denture not help already-infected people recover from those diseases. cleansers, toilet-bowl cleaners, and laundry/dry bleaches. 0016 Auchincloss, U.S. Pat. No. 4,822.512, discloses a 0021 Valliéres, U.S. Pat. No. 5,186,946, discloses a dis dry water-soluble biocide for inactivating certain types of infectant reportedly effective against bacteria, fungi, bacterial viruses, bacteria, and mold on non-human animals, specifi and fungal spores, and viruses. Somewhat similar to Auchin cally chickens, pigs, cows, and horses. The biocide contains closs's composition, Valliéres disinfectant consists of 60 to (a) 0.01 to 5 parts by weight of a water-soluble inorganic 90 weight % potassium hydrogen peroxymonosulfate, 2-10 halide, (b) 25 to 60 parts by weight of an oxidizing agent weight % malic acid, 2-6 weight % sulfamic acid, 0.25-3 which reacts, in aqueous solution, with the halide to generate weight% ethylene diamine tetraacetic acid disodium salt, and hypohalite ions, (c) 3 to 8 parts by weight of sulfamic acid, 1-15 weight% alkylated ether of polyethylene glycol surfac and (d) 10 to 30 parts by weight of an anhydrous alkali metal tant. Different from Auchincloss, Valliéres avoids the chlo phosphate subject to the total parts totaling 100. The biocide rine present in the sodium chloride preferably used by may include up to 20 parts by weight of a non-reducing Auchincloss to implement the inorganic halide in Auchin organic acid and up to 20 parts by weight of an organic closs’s biocide. Valliéres states that its disinfectant is to be Surfactant. used for cleaning instruments, floors, and bedding in hospi 0017. The preferred oxidizing agent in Auchincloss’s bio tals, bio-medical research centers, health centers, Veterinary cide is a persulfate or a peroxyphthalate. A persulfate is a hospitals, and clinics. Sulfur-oxygen-containing compound having more oxygen 0022. Potassium hydrogen peroxymonosulfate is also than a normal Sulfate. The additional oxygen in a persulfate is used for removing chloramines in Swimming pools. Regard present in the form of one or more peroxide units, a peroxide ing Swimming pools, Lightcap et al. ("Lightcap’), U.S. Pat. being a chemical compound which includes an oxygen-oxy No. 7,560,033 B2, discloses an anhydrous composition gen single bond. The main types of persulfates are peroxy formed with potassium hydrogen peroxymonosulfate and an monosulfates and peroxydisulfates. A peroxyphthalate is a active halogen agent for sanitizing water in recirculating compound having more oxygen than a normal phthalate, the water systems such as Swimming pools. The active halogen additional oxygen likewise being present in the form of one or agent consists of an alkali metal salt of dichloro-s-triazinetri more peroxide units. one or/and halogenated dimethylhydantoin. Lightcap reports 0.018 Auchincloss's oxidizing agent is normally potas that its composition inhibited the growth of algae in water and sium monopersulfate triple salt, i.e., 2KHSOs. KHSO. inactivated E. coli and Enterococcus faecium bacteria in KSO. The halide is preferably sodium chloride but can be Water. potassium chloride, potassium bromide, potassium iodide, (0023 Randeri et al. (“Randeri’), U.S. Pat. No. 3,873,696 Sodium bromide, or sodium iodide. The organic acid is pref discloses that contact lenses can be effectively cleaned with a erably malic or Succinic acid. The alkali metal phosphate can Solution containing an oxygen-releasing salt such as a thio be any one of sodium hexametaphosphate, monosodium sulfate, a persulfate, or a peroxydisulfate. Randeri's preferred US 2012/0074014 A1 Mar. 29, 2012

oxygen-releasing salt is potassium hydrogen peroxymono (Durante'), U.S. Pat. No. 7,442,323 B2. The solvent in the Sulfate provided from a triple salt also containing potassium solutions referred to in Tufano and Durante presumably was hydrogen sulfate (KHSO) and potassium sulfate (KSO). high-purity water. Randeri's solution normally contains a chloride-ion-releas 0028. The loss of active oxygen content of potassium ing salt Such as Sodium chloride. monopersulfate triple salt composition (KHSOs), (KHSO4), 0024 Potassium monopersulfate triple salt of the chemi (K2SO4) with time depends on various factors including storage conditions, temperature, and material purity, includ cal formula 2KHSOs. KHSO.KSO is an implementation of ing solution purity for (KHSOs), (KHSO), (K-SO) solu the more general chemical composition (KHSOs), (KHSO) tions. Regarding solution purity, (KHSO.), (KHSO.), (K2SO4), where x+y+Zare variable mole (or molar) fractions (K2SO4). Solutions made with normal water have greater loss whose sum is 1. The general composition (KHSOs), in oxygen content with time than (KHSO.), (KHSO.), (KHSO.), (KSO.) is referred to herein as “potassium (K2SO4). Solutions made with high-purity water because nor monopersulfate triple salt composition' where the word mal water contains a considerably higher content of metals “composition” distinguishes (KHSOs), (KHSO4), (K-SO). than catalyze (promote) the decomposition of potassium from the specific formulation 2KHSO.KHSOKSO. hydrogen peroxymonosulfate (KHSOs). In any event, the loss When mole fractions x, y, and Z respectively are 0.5,0.25, and in active oxygen content significantly reduces the potency of 0.25, the potassium monopersulfate triple salt composition potassium monoperSulfate triple salt composition (KHSOs), (KHSOs), (KHSO), (K2SO4) becomes potassium monoper (KHSO4)(K2SO4), especially in solution form. sulfate triple salt of the formula 2KHSO.KHSO.KSO. 0029 Potassium peroxymonosulfate triple salt composi 0025. A molecule of potassium hydrogen peroxymono tion (KHSOs), (KHSO4)(K2SO4), including potassium per Sulfate (KHSOs) functions as an oxidizer by decomposing oxymonosulfate triple salt 2KHSO.KHSO.KSO itself, and “releasing one of its oxygen atoms. The oxygen which can be manufactured in various ways. Martin, U.S. Pat. No. can be so released from potassium hydrogen peroxymono 7,090,820 B2, discloses a technique for manufacturing the sulfate is generally referred to as “active oxygen. Pure potas potassium monoperSulfate triple salt composition (KHSOs), sium hydrogen peroxymonosulfate has an active oxygen con (KHSO4)(K2SO4), with mole fractions x, y, and Zadjusted to tent of approximately 10.5%. achieve an active oxygen content greater than 4.5% and with a reduced content of potassium persulfate. In a first embodi 0026. The weight (mass) fractions of potassium hydrogen ment, X is 0.43-0.64, y is 0.15-0.43, and Z is 0.15-0.43. In a peroxymonosulfate (KHSOs), potassium hydrogen Sulfate second embodiment, X is 0.46-0.64, y is 0.15-0.37, and Z is (KHSO), and potassium sulfate (KSO) respectively are O.15-0.37. roughly 45%, 25%, and 30% in a common formulation of 0030 Martin's process for manufacturing the potassium potassium monopersulfate triple salt composition (KHSOs), triple salt composition so that mole fractions x, y, and Z fall (KHSO4)(K2SO4). This formulation has an active oxygen into the ranges of the second embodiment entails adding a content of approximately 4.7%. The active oxygen content of hydrogen peroxide solution containing at least 70% hydrogen potassium monopersulfate triple salt composition (KHSOs), peroxide by weight to a Sulfuric acid solution containing at (KHSO4), (K-SO), such as this formulation, is lower than least 90% sulfuric acid by weight at a sulfuric-acid-to-hydro the active oxygen content of potassium hydrogen peroxy gen-peroxide ratio which is substoichiometric to produce a monosulfate (KHSOs) itself due to the presence of non-oxi first Caro's acid solution containing peroxymonosulfuric acid dizing components potassium hydrogen Sulfate (KHSO) and (again, HSOs) and hydrogen peroxide. The first Caro's acid potassium Sulfate (K2SO4) in potassium monoperSulfate Solution is combined with oleum containing Sulfuric acid and triple Salt composition. A Small percentage of potassium per sulfur trioxide. The oleum reacts with water in the first Caro's sulfate (or potassium perdisulfate) of the chemical formula acid solution to produce a second Caro's acid solution. An KSOs may be present in potassium peroxymonosulfate alkali potassium compound is added to the second Caro's acid triple salt composition and in the specific potassium peroxy Solution to produce a partially neutralized solution containing monosulfate triple salt. The potassium persulfate is generally potassium monopersulfate triple salt composition (KHSOs), undesirable because it reduces the active oxygen content, for (KHSO4), (K-SO) in which x, y, and Z have values in the example, to 4.5%. A higher active oxygen content is often ranges of Martin's second embodiment. desired. 0031 Looking now at the background art in total, bacte 0027. The active oxygen content of potassium monoper rial, eukaryotic, prions, and viral pathogens cause many dis sulfate triple salt composition (KHSOs), (KHSO4)(K2SO4). eases to human. Success in treating these diseases varies decreases with time due to the decomposition of the potas widely. While treatments for some of these diseases are essen sium hydrogen peroxymonosulfate (KHSOs) and the atten tially fully successful, treatments for others are only partially dant release of some of the active oxygen. The decrease of Successful or do not currently exist. In particular, treatments active oxygen content with time is considerably greater for for allergic rhinitis, arthritis, bronchitis, hemorrhoids, urti Solutions containing potassium monopersulfate triple salt caria, toothache, tinea pedis, acute viral nasopharyngitis, her composition (KHSOs), (KHSO4), (K-SO) than for dry solid pes simplex, dandruff, itching, bromhidrosis, and vaginitis potassium monoperSulfate triple salt composition (KHSOs), are commonly weak or non-existent. Even when treatments (KHSO), (K-SO). In particular, anhydrous solid potassium are fully or partially successful, there are often adverse side monopersulfate triple salt 2KHSO.KHSOKSO loses effects to the treatments. roughly 1% of its active oxygen content per month as reported 0032 Sporkenbach’s technique of using a peroxymono in Tufano et al. (“Tufano), U.S. Pat. No. 6,818,142 B2. How Sulfuric acid salt, preferably potassium hydrogen peroxy ever, solutions of potassium monoperSulfate triple salt monosulfate, to inactivate certain viruses on animate and 2KHSOs. KHSO.KSO lose 3-5% of their active oxygen inanimate surfaces is an advancement. However, Sporken content per month as indicated in Tufano and Durante et al. bach’s viricidal technique is not useful in treating people to US 2012/0074014 A1 Mar. 29, 2012

recover from the diseases caused by those viruses. It is desir composition, the active material includes salt of peroxy able to have better techniques and medicinal products for monosulfuric acid or/and reaction product of the salt of per treating people infected with diseases caused by bacterial, oxymonosulfuric acid and other material of the composition. eukaryotic, prions, and viral pathogens and by non-patho The salt of peroxymonosulfuric acid is again typically prima genic inflammation. rily potassium hydrogen peroxymonosulfate. In another implementation of the semiliquid composition, the active GENERAL DISCLOSURE OF THE INVENTION material includes (a) inorganic halide or/and reaction product 0033. The present invention furnishes advanced products of the inorganic halide and other material of the composition Suitable for treating diseases and other debilitating medical and (b) an oxidizing agent or/and reaction product of the conditions caused by bacterial, eukaryotic, prion, and viral oxidizing agent and other material of the composition. The pathogens, including fungal, spore, and parasitic pathogens, oxidizing agent is again reactable in water with the inorganic and by non-pathogenic inflammation. The products provided halide to generate hypohalite ions. by the invention are also suitable for preventing debilitating 0039. The semiliquid composition in the first aspect of the medical conditions caused by bacterial, eukaryotic, prion, invention normally has a dynamic viscosity of at least 5 Pa-S and viral pathogens and by non-pathogenic inflammation. In at 25°C. The dynamic viscosity of the composition is nor addition, the products provided by the invention can be used mally no more than 5,000 Pa-s at 25° C. By providing the in other applications such as commercial and industrial appli composition in semiliquid form, particularly with a dynamic cations. viscosity of 5 to 5,000 Pa-s at 25°C., the shelf life of the 0034 More specifically, a product in a first aspect of the composition is expected to be extended while simultaneously invention is a disintegrable composition for introduction into enabling the composition to be readily administered. a liquid, normally water. The composition, normally consist 0040. A product in a third aspect of the invention is a ing of solid material, is of Such a structure that the composi container assembly consisting at least partially of a compo tion gradually disintegrates upon introduction into the liquid sition and a container that holds the composition. The com for enabling particles of the composition to disperse into the ponents of the composition, normally a liquid, include a car liquid so that the mass of the composition is 10% to 90% of rier and active material dispersed largely throughout the the initial mass value 1 hour to 100 days after the composition carrier. In one implementation of the container assembly, the is introduced into the liquid. The gradual disintegration of the active material includes salt of peroxymonosulfuric acid composition is generally referred to as metered release. or/and reaction product of the salt of peroxymonosulfuric 0035. The disintegrable composition contains active acid and other material of the composition. The salt of per material which is mainly responsible for the composition's oxymonosulfuric acid is once again typically primarily potas advantageous properties. In one implementation of the disin sium hydrogen peroxymonosulfate. In another implementa tegrable composition, the active material includes salt of per tion of the container assembly, the active material includes (a) oxymonosulfuric acid, typically primarily potassium hydro inorganic halide or/and reaction product of the inorganic gen peroxymonosulfate. In another implementation of the halide and other material of the composition and (b) an oxi disintegrable composition, the active material includes inor dizing agent or/and reaction product of the oxidizing agent ganic halide and an oxidizing agent reactable in water with and other material of the composition. The oxidizing agent is the inorganic halide to generate hypohalite ions. once again reactable in water with the inorganic halide to 0036. The rate of disintegration can be adjusted to accom generate hypohalite ions. modate various situations. Relatively fast metered release of 0041. The container blocks transmission of visible light, the disintegrable composition is, for example, useful in situ and typically also other radiation such as ultraviolet (“UV) ations where a person ingests a piece of the disintegrable radiation, incident on the container from outside the container composition to treat a debilitating medical condition. The in one embodiment of the product in the third aspect of the piece of the disintegrable composition then disintegrates in invention. This prevents visible light, and typically also Such liquid, normally water, in the person's body so that the result other radiation, from degrading the composition, thereby ant liquid composition is administered internally to the per enabling it to have extended shelflife at suitably high potency. son in a gradual manner. In another embodiment of this product, the composition is 0037 Relatively slow metered release of the disintegrable Subjected to an average pressure of more than 1 atm, prefer composition is useful in situations in which the potency of the ably at least 2 atm, inside the container. The elevated pressure liquid form of the composition needs to be maintained Suit inside the container assists in dispensing the product from the ably high for an extended period. A manufacturer of the liquid container while preventing material. Such as air, outside the composition can employ slow metered release of the disinte container from contaminating the composition and causing it grable composition to provide the liquid composition with to degrade. The shelf life at Suitably high potency is again extended shelf life at suitably high potency. A user of the extended. liquid composition can utilize slow metered release of the 0042. The product in the third aspect of the invention disintegrable composition for maintaining the potency of the normally includes a dispenser hermetically attached to the liquid composition Suitably high for an extended period Sub container for controllably dispensing the composition from sequent to combining the disintegrable composition with the the container. In a further embodiment of the product, the liquid. Additionally, by providing the disintegrable composi dispenser prevents material outside the container and the tion as Solid material, the disintegrable composition itself has dispenser from entering the container through the dispenser. a long shelf life. This similarly extends the shelf life by preventing material, 0038 A product in a second aspect of the invention is a Such as air, outside the container from contaminating the composition formed with a carrier and active material dis composition and causing it to degrade. The features of these persed largely throughout the carrier Such that the composi three embodiments may be variously combined in other tion is semiliquid. In one implementation of the semiliquid embodiments of this product. US 2012/0074014 A1 Mar. 29, 2012

0043 A product in a fourth aspect of the invention is a persed largely throughout the carrier, and an inhibitor dis multiple-container assembly consisting at least partially of a persed largely throughout the carrier. The active material first container, a second container, and a combining element includes an oxidizing agent or/and reaction product of the attached to or integral with at least one of the containers. The oxidizing agent and other material of the composition. The first container contains a liquid carrier. The second container oxidizing agent contains active oxygen that consists of contains a primary composition containing active material. chemically readily transferable oxygen atoms. The inhibitor The combining element enables matter of the primary com inhibits the composition from losing active oxygen. As a position and matter of the carrier to be combined to form a result, the potency of the inhibitor-containing composition is further composition. maintained at a suitably high level for extended time so that 0044) The active material includes salt of peroxymonosul the composition has increased shelf life. furic acid, again typically primarily potassium hydrogen per 0.052 The oxidizing agent in one implementation of the oxymonosulfate, in one implementation of the double-con inhibitor-containing composition is salt of peroxymonosul tainer assembly. In another implementation of the multiple furic acid, normally primarily potassium hydrogen peroxy container assembly, the active material includes inorganic monosulfate. In another implementation of the inhibitor-con halide and an oxidizing agent reactable in water with the taining composition, the active material includes inorganic inorganic halide to generate hypohalite ions. halide in addition to the oxidizing agent. With the liquid 0045 All the material of the primary composition is nor carrier including water in this implementation, the oxidizing mally solid material. The further liquid composition created agent is reactable in water with the inorganic halide to gen by combining matter of the primary composition and matter erate hypohalite ions. of the carrier need not be formed until shortly before the 0053. In short, the invention furnishes a variety of prod further liquid composition is administered to a person. As a ucts having extended shelf life. The products of the invention result, the multiple-container assembly has a long shelf life. are suitable for treating diseases and other debilitating medi 0046. A product in a fifth aspect of the invention is a cal conditions caused by bacterial, eukaryotic, prion, and composition containing a plurality of Solid particles consist viral pathogens, including fungal, spore, and parasitic patho ing of Support material and active material. Because the par gens, and by non-pathogenic inflammation and for preventing ticles are solid, the particle-containing composition has along debilitating medical conditions caused by bacterial, eukary shelf life. otic, prion, and viral pathogens and by non-pathogenic 0047. The active material includes salt of peroxymonosul inflammation. The products of the invention can also be used furic acid, once again typically primarily potassium hydrogen in other applications. The invention thereby provides a large peroxymonosulfate, in one implementation of the particle advance over the prior art. containing composition. The salt of peroxymonosulfuric acid is present in the particles at an average mass percentage of no BRIEF DESCRIPTION OF THE DRAWINGS more than 10%. The support material is normally non-reac tive with the salt of peroxymonosulfuric acid and with reac 0054 FIG. 1 is a side cross-sectional view of a container tion product of the Salt of peroxymonosulfuric acid and any assembly in accordance with the invention for dispensing a other material of the composition when it is dry or combined medicinal drug. with water. 0055 FIGS. 2a and 2b are side cross-sectional views of a 0048. In another implementation of the particle-contain typical embodiment of the dispenser in the container assem ing composition, the active material includes inorganic halide bly of FIG. 1 respectively in the non-actuated and actuated and an oxidizing agent reactable in water with the inorganic conditions. halide to generate hypohalite ions. The oxidizing agent is 0056 FIG. 3 is a side cross-sectional/schematic view of a present in the particles at an average mass percentage of no double-container assembly in accordance with the invention more than 10%. The support material is normally non-reac for dispensing a medicinal drug. tive with the oxidizing agent and with reaction product of the 0057 FIG. 4 is a side cross-sectional view of a powder of oxidizing agent and any other material of the composition particles that contain a medicinal drug in accordance with the when it is dry or combined with water. invention. 0049. The particles containing either implementation of 0058. Like reference symbols are used in the drawings and the particle-containing composition are normally so Small in the description of the preferred embodiments to represent that they form a powder. In particular, the average diameter of the same, or very similar, item or items. the particles is normally no more than 500 um. 0050. A further composition is formed by combining the DESCRIPTION OF THE PREFERRED particles containing either implementation of the particle EMBODIMENTS containing composition with a liquid carrier, normally water. 0059 Persons afflicted with diseases and other debilitat The liquid carrier promotes chemical reactions involving the ing medical conditions caused by bacterial, eukaryotic, prion, active material. However, the particle Support material and and viral pathogens, including fungal, spore-caused, and the liquid carrier can readily be chosen so that the Support parasitic infections, and by non-pathogenic-caused inflam material is chemically non-reactive in the presence of the mation are treated with a medicinal drug formed at least carrier. As a result, comparatively fewer chemical reactions partially with salt, i.e., one or more individual salts, of per involving the active material are expected to occur. This, in oxymonosulfuric acid (H2SOs). Such a salt is generally turn, is expected to enable the further composition to have referred to as a peroxymonosulfate. The medicinal drug Suitably high potency for increased time Subsequent to com formed at least partially with peroxymonosulfate is referred bining the particles with the liquid carrier. to herein as being of type I. The medicinal drug of type I can 0051 A product in a sixth aspect of the invention is a also be administered to persons for preventing them from composition containing a liquid carrier, active material dis contracting debilitating medical conditions caused by bacte US 2012/0074014 A1 Mar. 29, 2012 rial, eukaryotic, prion, and viral pathogens, including fungal, cesium hydrogen peroxymonosulfate may respectively be spore-caused, and parasitic infections, and by non-patho referred to simply as rubidium peroxymonosulfate and genic-caused inflammation. cesium peroxymonosulfate. 0060 Peroxymonosulfates are generally strong oxidizing 0065. The alkaline earth metal salts of peroxymonosulfu agents, i.e., they readily provide (or release) oxygen under ric acid consist of its alkaline earth metal salts and its alkaline certain conditions at standard temperature (20-25° C.) and earth metal hydrogen salts. For primary alkaline earth metals standard pressure (760 torr). In particular, oxygen is readily magnesium and calcium, the alkaline earth metal salts of released by a peroxymonosulfate when it is present in water, peroxymonosulfuric acid are magnesium peroxymonosulfate typically in aqueous solution. The active oxygen content R. i.e., fraction or percentage ofreadily providable oxygen, of an (MgSOs), magnesium dihydrogen diperoxymonosulfate oxidizing agent Such as a peroxymonosulfate is given gener (MgH2(SOs)), calcium peroxymonosulfate (CaSOs), and ally as: calcium dihydrogen diperoxymonosulfate (CaFI (SOs)). 0.066 Beryllium, barium, and strontium are additional Rao-mao/moxag WoWWoxag (1) alkaline earth metals. To the extent manufacturable without where m is the mass of the active oxygen in the oxidizing being toxic, the alkaline earth metal salts of peroxymonosul agent, m is the mass of the oxidizing agent, W is the furic acid further include beryllium peroxymonosulfate molecular weight of oxygen, N is the number of moles of (BeSOs), beryllium dihydrogen diperoxymonosulfate (BeH, active oxygen in a mole of the oxidizing agent, and W is (SOs)), barium peroxymonosulfate (BaSOs), barium dihy the molecular weight of the oxidizing agent. drogen diperoxymonosulfate (BaH2(SOs)), strontium per 0061 Oxygen's molecular weight W is approximately oxymonosulfate (SrSOs), and strontium dihydrogen 16.00. Accordingly, active oxygen content R is more par diperoxymonosulfate (SrH2(SOs)). ticularly given as: 0067. An ammonium salt of peroxymonosulfuric acid is chemically representable as NRRRRHSO5 or as NRR Ros16.00N, Woxo (2) R. R.NR,R,R,R,SOs where each of R. R. R. R. R. R. The oxidizing capability of the peroxymonosulfate used in RandR, is variously hydrogen or a hydrocarbon group such forming the medicinal drug of type I is believed to be a factor as an alkyl, cycloalkyl, aryl, or aralkyl group. For the NRR in the drug's effectiveness in combating bacterial, eukaryotic, R. R.NR,R,R,R,SOs ammonium peroxymonosulfates, R, prion, and viral pathogens that attack humans and in causing R. R. and R, are typically respectively the same as R. R. non-pathogenic-caused inflammation to be reduced in R, and R. The non-carbon ammonium salts of peroxymono humans. Eq. 2 thus provides an estimate of the oxidizing Sulfuric acid are ammonium hydrogen peroxymonosulfate capability of the peroxymonosulfate used informing the drug (NHHSOs) and diammonium peroxymonosulfate ((NH4) of type I. SOs). Ammonium hydrogen peroxymonosulfate may be 0062. The peroxymonosulfates include alkali metal salts, referred to simply as ammonium peroxymonosulfate. alkaline earth metal salts, and ammonium (group) salts of 0068 Peroxymonosulfuric acid may also form salts with peroxymonosulfuric acid. Such a peroxymonosulfate is metals in parts of the Periodic Table other than the alkali chemically representable as M.H.(SOs), where M is an alkali metals of Group 1a and the alkaline earth metals of Group 1b. metal in Group 1a of the Periodic Table, an alkaline earth For instance, peroxymonosulfuric acid may form salts with metal in Group 1b of the Periodic Table, or an ammonium metals, e.g., zinc, in Group 2b of the Periodic Table. To the group and where i, j, and k are integers. Integers i, j, and k extent manufacturable, the Group 2b Salts of peroxymono satisfy the relationship ni+ equals 2k where n is an integer Sulfuric acid include Zinc peroxymonosulfate (ZnSOs) and equal to 1 for an alkali metal or an ammonium group and Zinc dihydrogen diperoxymonosulfate (ZnH2(SOs)). equal to 2 for an alkaline earth metal. Integerican be 0 such 0069. The salt of peroxymonosulfuric acid used in form that hydrogen is absent in the H, term of M.H.(SO.). ing the medicinal drug of type I is preferably potassium 0063. The alkali metal salts of peroxymonosulfuric acid hydrogen peroxymonosulfate (KHSOs). In a molecule of consist of its alkali metal hydrogen salts and its dialkali metal potassium hydrogen peroxymonosulfate, a pair of oxygen salts. For primary alkali metals lithium, Sodium, and potas atoms singly bonded to each other are situated between the sium, the alkali metal salts of peroxymonosulfuric acid are Sulfur and hydrogen atoms. The single oxygen-oxygen bond lithium hydrogen peroxymonosulfate (LiHSOs), dilithium readily breaks under certain conditions, e.g., when the mol peroxymonosulfate (LiSOs), Sodium hydrogen peroxy ecule of potassium hydrogen peroxymonosulfate is dissolved monosulfate (NaHSOs), disodium peroxymonosulfate in a suitable solvent such as water, to release one of the (NaSOs), potassium hydrogen peroxymonosulfate oxygen atoms involved in the single oxygen-oxygen bond. (KHSOs), and dipotassium peroxymonosulfate (KSOs). The molecular weight Wiscs of potassium hydrogen per Similar to potassium hydrogen peroxymonosulfate often oxymonosulfate is approximately 152.17. Potassium hydro referred to as potassium peroxymonosulfate, lithium hydro gen peroxymonosulfate has one mole of active oxygen per gen peroxymonosulfate and Sodium hydrogen peroxymono mole of potassium hydrogen peroxymonosulfate. Utilizing sulfate may respectively be referred to simply as lithium Eq. 2 given above, active oxygen content R of pure potas peroxymonosulfate and sodium peroxymonosulfate. sium hydrogen peroxymonosulfate is approximately 10.5%. 0.064 Rubidium and cesium are additional alkali metals. 0070 The potassium hydrogen peroxymonosulfate used To the extent manufacturable without being toxic, the alkali in forming the medicinal drug of type I is normally provided metal salts of peroxymonosulfuric acid further include as a component of a multiple salt, preferably potassium rubidium hydrogen peroxymonosulfate (RbHSOs), diru monopersulfate triple salt composition (KHSOs), (KHSO4), bidium peroxymonosulfate (Rb2SOs), cesium hydrogen per (KSO) for which the Sum of mole fractions x, y, and Z oxymonosulfate (CSHSOs), and dicesium peroxymonosul equals 1. Potassium hydrogen Sulfate (KHSO) and potas fate (CSSOs). Rubidium hydrogen peroxymonosulfate and sium Sulfate (K2SO4), again sometimes referred to as dipo US 2012/0074014 A1 Mar. 29, 2012

tassium Sulfate, are physically bonded to potassium hydrogen 0074 The active oxygen content R, i.e., fraction or per peroxymonosulfate in potassium monoperSulfate triple salt centage of active oxygen, in potassium monopersulfate triple composition. salt composition is given in terms of mole fractions x, y, and 0071 Neither potassium hydrogen sulfate nor potassium Z by the relationship: Sulfate readily releases oxygen under the same conditions at standard temperature and pressure for which potassium hydrogen peroxymonosulfate readily releases oxygen. The overall oxidizing agent formed with potassium monopersul as 16.00x f (152.17x + 136.17y + 174.263) fate triple salt composition normally used in forming the medicinal drug of type I thereby consists of (a) active oxygen where W is again the molecular weight of oxygen. For the releasing material formed by potassium hydrogen peroxy preceding formulation in which mole fractions x, y, and Z monosulfate and (b) other material, referred to here as inac respectively are 0.5, 0.25, and 0.25, active oxygen content tive material, consisting of potassium hydrogen Sulfate and R is approximately 5.2%. potassium sulfate. (0075) The mole fraction F of component C in a general I0072. The mass fraction F of a component C of agen product is, in turn, given as: eral product having in components C. . . . C. . . . C. each being of a molecular weight W and of a mole fraction F, in Frn ( F. (8) the product, is given as: F-(r)/S () Accordingly, mole fractions X, y, and Z respectively of potas (3) sium hydrogen peroxymonosulfate, potassium hydrogen Sul F = W. FM / X, W, Fu, fate, and potassium sulfate in potassium monoperSulfate q=l triple salt composition (KHSOs), (KHSO), (K-SO.) are respectively given in terms of mass fractions F2sos. where q is an integer varying from 1 to n and where the Sum F. Kriso4; and F, K2so4 as: of mole fractions F. . . . F. . . . F., equals 1. The molecular Weights Wasos, W-soa, and W2so of potas X (i. ) /(i. -- FinkHSO4 -- (ii) (9) sium hydrogen peroxymonosulfate, potassium hydrogensul WKHSO5 WKHSO5 WKHSO4 WK2SO4 s -- -- fate, and potassium sulfate respectively are 152.17, 136.17. (i.152.17 ) /(;;152.17 FinkHSO4136.17 'E)174.26 and 174.26 (to two significant digits beyond the decimal point). Letting FK2.sos., F.Krasoa, and F&2so represent the y = (i. ) /(i. -- FinkHSO4 () (10) respective mass fractions of potassium hydrogen peroxy WKHSO4 WKHSO5 WKHSO4 WK2SO4 monosulfate, potassium hydrogen Sulfate, and potassium Sul s (Fig. ) /(i.e., -- FinkHSO4 -- fi;) fate in potassium monoperSulfate triple salt composition 136.17 152.17 136.17 174.26 (KHSOs), (KHSO4), (K2SO4), mass fractions Fasos, 3. (ii) /(i. -- FinkHSO4 () (11) FKriso, and Fuk2so are respectively given interms of mole WK2SO4 WKHSO5 WKHSO4 WK2SO4 fraction X of potassium hydrogen peroxymonosulfate, mole Fink2SO4 FinkHSO5 FinkHSO4. Fink2SO4 fraction y of potassium hydrogen Sulfate, and mole fraction Z s (E)/(+174.26 152.17 136.17 +E)174.26 of potassium Sulfate as: 0076 Mass fractions F.Krzsos F.Krasoa, and Fik2so4 respectively are approximately 45%, 25%, and 30% in another formulation of potassium monopersulfate triple salt FKHSO5 = WKHSO5.X f(WKHSO5 x + WKHSO4y + WK2SO42.) (4) composition used informing the medicinal drug of type I. Use as 152.17x (152.17x + 136.17y + 174.263) of Eqs. 9-11 yields the following values for mole fractions x. FKHSO4 = WKHSO4X f(WKHSO5 x + WKHSO4y + WK2SO42.) (5) y, and Z in this second formulation: (a) mole fraction X of as 136.17x (152.17x + 136.17y + 174.263) potassium hydrogen peroxymonosulfate is approximately 46%, (b) mole fraction y of potassium hydrogen Sulfate is FK2SO4 = WK2SO4X f(WKHSO5 x + WKHSO4 y + WK2SO42.) (6) approximately 28%, and (c) mole fraction y of potassium as 174.26x f (152.17x + 136.17y + 174.263) sulfate is approximately 26%. The second formulation of the potassium monoperSulfate triple salt composition is then 0073 Potassium monopersulfate triple salt composition is approximately given as (KHSOs)a(KHSO)os(KSO). implemented with potassium monopersulfate triple salt 26 or approximately equivalently as 1.7KHSOs. 1.1KHSO. (2KHSOs. KHSOKSO) in one formulation used in form KSO. ing the medicinal drug of type I. Inasmuch as mole fractions 0077 Active oxygen content R is given interms of mass x, y, and Z respectively are 0.5, 0.25, and 0.25 in this formu fraction F, Krzsos as: lation, use of Eqs. 4-6 yields the following values for mass fractions F.K.2sos, F.Krasoa, and FK2soa in this formulation: (a) mass fraction Fiscs of potassium hydrogen peroxy RAO = (Wof WKHSO5) FKHSO5 (12) monosulfate is approximately 50%, (b) mass fraction as (16.00 f 152.17) Fusos Flso of potassium hydrogen Sulfate is approximately 22%, and (c) mass fraction F2s of potassium Sulfate is & O. 1051 FKHSos approximately 28%. US 2012/0074014 A1 Mar. 29, 2012

For the second formulation of potassium monopersulfate tion containing potassium monopersulfate triple salt compo triple salt composition in which mass fraction Fusos is sition (KHSOs), (KHSO4), (K-SO). The partially neutral approximately 45%, active oxygen content R is approxi ized solution is concentrated to form a slurry of the potassium mately 4.7%. monopersulfate triple salt composition at a desired specific 0078. The medicinal drug of Type I may be formed with a gravity, e.g., 1.55-1.65. The slurry is typically formed by Small percentage, normally no more than a few percent by mixing in a vacuum evaporator at a temperature of no more mass, typically no more than 1% by mass, of one or more than 35°C. The slurry is separated into mother liquor and other potassium-sulfur-oxygen salts, such as potassium per solids of which the solids contain the monopersulfate triple Sulfate (KSOs), present as impurity in the potassium salt composition. The Solids are dried at a temperature of no monopersulfate triple salt composition. Although this might more than 90° C., preferably no more than 70° C. Further cause the resultant composition of potassium hydrogen per details on this process are presented in Martin, the contents of oxymonosulfate, potassium hydrogen Sulfate, potassium Sul which are incorporated by reference herein. fate, and each other potassium-Sulfur-oxygen salt to strictly I0083. By suitably controlling the process conditions, mole be a multiple salt of at least four potassium-sulfur-oxygen fractions x, y, and Z of the potassium monoperSulfate triple salts, the resultant composition is substantially potassium salt composition (KHSOs), (KHSO4), (K-SO.) fall into the monopersulfate triple salt composition because the impurity following ranges. Broadly, X is 0.43-0.64, y is 0.15-0.43, and potassium-sulfur-oxygen salt constitutes only a small per Z is 0.15-0.43. More narrowly, X is 0.46-0.64, y is 0.15-0.37, centage by mass of the resultant composition. Furthermore, and Z is 0.15-0.37. the potassium hydrogen peroxymonosulfate, potassium I0084. The specific values of mole fractions x, y, and Z hydrogen Sulfate, and potassium sulfate used in forming the within the preceding ranges are often selected so that active resultant composition still constitute potassium monoperSul oxygen content R of the resultant formulation of the potas fate triple salt composition. sium monoperSulfate triple salt composition is greater than 007.9 The medicinal drug of type I may be formed with the approximate 4.7% active oxygen content of the second one or more components in addition to salt of peroxymono formulation of potassium monopersulfate triple salt compo Sulfuric acid and, when the salt of peroxymonosulfuric acid sition in which mass fraction Fesos of potassium hydrogen consists of potassium hydrogen peroxymonosulfate provided peroxymonosulfate is approximately 45% and in which cor as a component of potassium monopersulfate triple salt com responding mole fraction X of potassium hydrogen peroxy position, one or more components in addition to potassium monosulfate is approximately 46%. For instance, mole frac hydrogen sulfate, potassium sulfate, and any impurity in the tions x, y, and Z are typically chosen active oxygen content potassium monoperSulfate triple salt composition. The com R of the formulation of the potassium monoperSulfate ponents used to form the drug of type I are preferably all water triple salt composition is greater than 4.9%. At the same time, soluble such that the drug of type I is water soluble. The drug the amount of potassium persulfate in the formulation of the of type I is, as discussed further below, typically provided in potassium monopersulfate triple salt composition is less than a therapeutically inactive pharmaceutically acceptable car 0.5% by mass. rier, often water in which the components used to form the I0085 Increasing mole fraction X of potassium hydrogen drug are dissolved. One or more of the components used to peroxymonosulfate in potassium monoperSulfate triple salt form the drug of type I may, nonetheless, be non-soluble in composition (KHSO5),(KHSO),(K2SO4), generally causes water. In that case, each non-water-soluble component is active oxygen content R to increase. For example, an R. normally in liquid form or colloidably suspendable in water. value of 5.2%, and thus greater than 4.7%, is achieved with 0080 Formulations of potassium peroxymonosulfate the first-mentioned formulation in which mole fractions x, y, triple salt composition Suitable for use informing the medici and Z respectively are 0.5, 0.25, and 0.25. Active oxygen nal drug of type I can be manufactured in various ways. It is content R of potassium monopersulfate triple Salt compo typically desirable that a (KHSO.), (KHSO.), (KSO.) for sition can be made greater than 6% by choosing mole fraction mulation used in forming the drug of type I have a higher X of potassium hydrogen peroxymonosulfate to beat, or close active oxygen content, and a lower potassium persulfate to, the upper limit of 0.64 in the two sets of mole fraction impurity content, than the second formulation of potassium ranges given above. As another example, use of Eq. 7 yields monopersulfate triple salt composition in which mass frac an R value of approximately 6.7% when mole fraction X is tion Fusos is approximately 45%. 0.64 and mole fractions y and Z both are 0.18. 0081. With reference to Martin, cited above, a suitable I0086. As described in Martin, the foregoing process can be process for manufacturing the potassium triple salt composi modified in various ways. For instance, a Suprastoichiometric tion entails first adding a hydrogen peroxide (H2O) Solution Sulfuric-acid-to-hydrogen-peroxide ratio can be used instead containing at least 70% hydrogen peroxide by mass to a of a Substoichiometric Sulfuric-acid-to-hydrogen-peroxide sulfuric acid (HSO) solution containing at least 90% sulfu ratio. In that case, mole fractions x, y, and Z of the potassium ric acid by mass at a Substoichiometric Sulfuric-acid-to-hy monopersulfate triple salt composition (KHSOs), (KHSO4), drogen-peroxide ratio to produce a first Caro's acid solution (KSO) fall into the further narrowed range set in which x is containing peroxymonosulfuric acid and hydrogen peroxide. 0.53-0.64, y is 0.15-0.37, and Z is 0.15-0.37. The first Caro's acid solution is then combined with oleum I0087. When mole fractionX equals 0.53 at the lowerend of containing sulfuric acid and sulfur trioxide (SO). The oleum the mole fraction range for potassium hydrogen peroxymono reacts with water in the first Caro's acid solution to produce a sulfate in this third set of mole fraction ranges, use of Eq. 7 second Caro's acid solution. The temperature is maintained yields an R value of approximately of 5.5% when mole below 30°, normally below 20° C., during the preceding fractions y and Z both are 0.235. Since the upper limit of mole steps. fraction X is 0.64 in this third set of mole fraction ranges, 0082. A potassium compound is added to the second active oxygen content R of potassium monoperSulfate Caro's acid solution to produce a partially neutralized solu triple salt composition can readily be chosen to be 5.5-6.8% US 2012/0074014 A1 Mar. 29, 2012

by choosing mole fractions x, y, and Z to appropriately fall strontium bromide (SrBr), barium bromide (BaBr), ammo into this third set of mole fraction ranges. nium bromide (NH-Br), lithium iodide (LiI), sodium iodide 0088 People afflicted with diseases and other debilitating (NaI), potassium iodide (KI), rubidium iodide (Rb1), cesium medical conditions caused by bacterial, eukaryotic, prion, iodide (CsI), beryllium iodide (Be), magnesium iodide and viral pathogens, again including fungal, spore-caused, (MO2), calcium iodide (Cal.), strontium iodide (Sr.), and parasitic infections, and by non-pathogenic-caused barium iodide (Bal), and ammonium iodide (NHI) provided inflammation are treated with a medicinal drug formed at that such other halide does not react with the alkali metal least partially with water-soluble inorganic halide and an phosphate to form an insoluble salt. oxidizing agent reactable in water, typically aqueous solu tion, with the halide to generate hypohalite ions. The medici 0092. The alkali metal phosphate is normally one or more nal drug is also normally formed at least partially with (anhy of Sodium metaphosphate ((NaPO)), monosodium phos drous) alkali metal phosphate and Sulfamic acid. The phate (NaH2PO), disodium phosphate (NaHPO), triso chemical formula for Sulfamic acid, alternatively known as dium phosphate (NaPO), tetrasodium pyrophosphate amidosulfonic acid, amidosulfuric acid, aminosulfonic acid, (NaPO7), potassium metaphosphate ((KPO)), monopo and sulfamidic acid, is HNSO. The medicinal drug formed tassium phosphate (KHPO), dipotassium phosphate at least partially with the preceding four components is (KHPO), tripotassium phosphate (KPO), and tetrapotas referred to herein as being of type II. The medicinal drug of sium pyrophosphate (KPO). For each of sodium meta type II can also be administered to persons for preventing phosphate and potassium metaphosphate, n is a plural integer, them from contracting debilitating medical conditions caused i.e., n is 2 or more. Sodium metaphosphate can, for example, by bacterial, eukaryotic, prion, and viral pathogens, including be implemented with sodium hexametaphosphate ((NaPO) fungal, spore-caused, and parasitic infections, and by non e) or/and sodium trimetaphosphate ((NaPO)). Potassium pathogenic-caused inflammation. metaphosphate can similarly be implemented with potassium 0089. The oxidizing agent used in forming the medicinal hexametaphosphate (KPO)) or/and potassium trimeta drug of type II contains active oxygen-releasing material that phosphate (KPO)). readily releases oxygen under certain conditions at standard 0093. The material used to form the medicinal drug of type temperature and standard pressure. More particularly, oxygen II may include a non-reducing organic acid, normally malic is readily released by the active-oxygen-releasing material acid (HOCCHCHOHCOH) or succinic acid when it is present in water, typically in aqueous solution. The (HOCCHCH-COH). The ratio of the mole fraction F oxidizing agent typically may include additional oxygen ROA of the non-reducing organic acid to mole fraction For containing material, referred to here as inactive material, of the active oxygen-releasing material in the drug of type II which does not readily release oxygen under the same con is normally 0.01-50, preferably 0.05-5, more preferably 0.1- ditions at Standard temperature and pressure for which the 1, typically 0.25. active oxygen-releasing material readily releases oxygen. 0094. The material used to form medicinal drug of type II 0090 The ratio of the mole fraction F of the inorganic may also include a surfactant, typically sodium dodecylben halide to the mole fraction For of the active oxygen Zene sulfonate (NaCHSO). Other candidates for the sur releasing material in the medicinal drug of type II is normally factant are lauryl ether sulfates, ethylene oxide?propylene 0.01-4, preferably 0.02-2, more preferably 0.03-1, even more oxide alkyl phenol condensates, polyglycol ethers of fatty preferably 0.04-0.5, typically 0.06-0.18. The ratio of the mole alcohols, fatty acid ethylene oxide condensates, polyglycol fraction F of the alkali metal phosphate to mole fraction ethers of aklyn phenols, and fatty alcohol ethoxylates. The For of the active oxygen-releasing material in the drug of ratio of the mole fraction Fs of the surfactant to mole type II is normally 0.04-40, preferably 0.1-5, more preferably fraction For of the active oxygen-releasing material in 0.2-1, typically 0.4 The ratio of the mole fraction Fs of the drug of type II is normally 0.03-30, preferably 0.05-10, Sulfamic acid to mole fraction F of the active oxygen more preferably 0.1-10, typically 0.3. releasing material in the drug of type II is normally 0.03-30, 0.095 The medicinal drug of type II is, as discussed further preferably 0.1-10, more preferably 0.2-1, typically 0.35-0.7. below, often provided in a therapeutically inactive pharma 0091. The inorganic halide is normally sodium chloride ceutically acceptable liquid carrier, normally water. Each of (NaCl), an alkali metalhalide. The inorganic halide can alter the components, including the oxidizing agent, of the mate natively or additionally include one or more other alkali metal rial used to form the drug of type II is then soluble, e.g., water halides, one or more alkaline earth metal halides, or/and one soluble, in the carrier, colloidably suspendable in the carrier, or more ammonium halides. In particular, the inorganic or in liquid form so as to be miscible or emulsible with the halide can alternatively or additionally include one or more of carrier. The components used to form the drug of type II are lithium fluoride (LiF), sodium fluoride (NaF), potassium preferably all water soluble such that the drug of type II is fluoride (KF), rubidium fluoride (RbF), cesium fluoride water soluble. (CsP), beryllium fluoride (BeF), magnesium fluoride 0096. The active-oxygen-releasing material in the oxidiz (MgF), calcium fluoride (CaF), strontium fluoride (SrF), ing agent for the medicinal drug of type II normally includes barium fluoride (BaF), ammonium fluoride (NHF), lithium persulfate or/and peroxyphthalate. Persulfate candidates for chloride (LiCl), potassium chloride (KCl), rubidium chloride the active-oxygen-releasing material include peroxymono (RbCl), cesium chloride (CsCl), beryllium chloride (BeCl), Sulfates (having SOs groups) and peroxydisulfates (having magnesium chloride (MgCl), calcium chloride (CaCl), SOs groups). The active-Oxygen-releasing material pref strontium chloride (SrCl), barium chloride (BaCl), ammo erably includes peroxymonosulfate, i.e., salt of peroxymono nium chloride (NHCl), lithium bromide (LiBr), sodium bro Sulfuric acid, such as alkali metal salt, alkaline-earth metal mide (NaBr), potassium bromide (KBr), rubidium bromide salt, or/and ammonium salt of peroxymonosulfuric acid. (RbBr), cesium bromide (CsBr), beryllium bromide (BeBr), More preferably, the salt of peroxymonosulfuric acid magnesium bromide (MgBr), calcium bromide (CaBr), includes potassium hydrogen peroxymonosulfate. US 2012/0074014 A1 Mar. 29, 2012

0097. Other sulfur-containing candidates for the active drug of type II. The composite drug of types I and II is referred oxygen-releasing material in the oxidizing agent for the to here as the medicinal drug of “type I/II. medicinal drug of type II include thiosulfates (having SO, 0101 The medicinal drug of type I/II is preferably formed groups). A peroxyphthalate candidate for the active-oxygen with potassium hydrogen peroxymonosulfate as the active releasing material is potassium monoperoxyphthalate. The oxygen-releasing material, sodium chloride as the inorganic active-oxygen-releasing material can alternatively or addi halide, Sodium hexametaphosphate as the alkali metal phos tionally be implemented with chlorine-oxygen-containing phate, Sulfamic acid, malic acid as the non-reducing organic compounds such as hypochlorites (having CIO groups), acid, and sodium dodecylbenzene Sulfonate as the Surfactant. chlorites (having CIO groups), chlorates (having ClO. The potassium hydrogen peroxymonosulfate in this formula groups), and perchlorates (having CIO groups) and with tion is normally provided as a component of potassium other analogous halogen compounds. One hypochlorite monopersulfate triple salt composition. The mass fractions of example is sodium hypochlorite (NaClO). potassium hydrogen peroxymonosulfate, potassium hydro 0098. To the extent not mentioned above, the active-oxy gen Sulfate, and potassium sulfate in potassium monopersul gen-releasing material in the oxidizing agent for the medici fate triple salt composition (KHSO.), (KHSO,), (KSO.) are nal drug of type II may include oxygen-releasing salts such as approximately 45%, 25%, and 30% in this formulation so that alkali metal salts (particularly potassium, Sodium, and mole fractions x, y, and Z are respectively approximately lithium salts), alkaline earth metal salts (particularly calcium 46%. 28%, and 26%. and magnesium salts), and ammonium salts of other inor 0102. As mentioned above, neither potassium hydrogen ganic and organic acids. Other candidates for the active Sulfate nor potassium sulfate readily releases oxygen under oxygen-releasing material are the alkali metal and ammo the same conditions at Standard temperature and pressure for nium salts of permanganic acid (HMnO), especially which potassium hydrogen peroxymonosulfate readily potassium permanganate (KMnO) but also potentially releases oxygen. Consequently, the potassium hydrogen Sul lithium permanganate (LiMnO), sodium permanganate fate and potassium Sulfate in potassium monoperSulfate triple (NaMnO), rubidium permanganate (RuMnO), cesium per salt composition of potassium monoperSulfate triple salt manganate (CsMnO), and ammonium permanganate composition constitute inactive material of the material used (NHMnO). Insofar as the drug of type II is provided in a to form the preceding preferred formulation of the medicinal therapeutically inactive pharmaceutically acceptable liquid drug of type I/II. carrier, again normally water, all of these candidates for the (0103) The number M of moles of each component C active-oxygen-releasing material need to be soluble, e.g., used in forming a multi-component product consisting of a water soluble, in the carrier, colloidably suspendable in the total of M moles is: carrier, or in liquid form so as to be miscible or emulsible with the carrier. M-FMr (13) 0099. The oxidizing agent for the medicinal drug of type II where F again is the mole fraction of component C and may further include peroxide (O-O anion) including where the sum of all mole fractions F again equals 1. The hydrogen peroxide (H2O), oxide (Of anion) including Sub molar ratio R is the ratio of the number M, of moles of a oxide (also Ofanion), chromium trioxide (CrOs), osmium component C, in the product to the number M of moles of a tetroxide (OsO4), and chlorine dioxide (CIO), dioxygenyl component C, in the product. Using Eq. 13, molar ratio R, compound (O." ion), oxyanion compound (AO, ion where A is an element and Z is a charge number), peroxydisulfate (also denominated as persulfate) (SOs anion) including ammonium peroxydisulfate ((NH4)2SOs), potassium per The parameter F/F is the mole fraction ratio Ra, i.e., oXydisulfate (KSOs), and Sodium peroxydisulfate the ratio of the mole fraction F, of component C, in the (Na2SOs), sulfoxide (R-S(=O) R'), sulfite (SO, product to the mole fraction F of component Ca in the anion), sulfur dioxide (SO), nitrate (NO anion), chromate product. Hence, mole fraction ratio R, equals molar ratio (CrO, anion) including pyridinium chlorochromate, RMe?a dichromate (CrO, anion), phosphite (PO, anion), hypo 0104. Using Eq. 8, mole fraction ratio R, and molar phosphite (HPO anion), oxoacid (or oxyacid) including ratio Ratt, are given as: Sulfur oxoacid and phosphorus oxoacid, peracetic acid (CH-COH), ascorbic acid (CHO), formic acid (HCO2H), or/and oxalic acid (CH2O). Fmb 6) (15) 0100 When the active-oxygen-releasing material consists RFMbia = RMba = ( W, at least partially of salt of peroxymonosulfuric acid Such as potassium hydrogen peroxymonosulfate, the medicinal drug of type II implements the medicinal drug of type I for the where F and F, are the respective mass fractions of com situation in which the drug of type I is formed with salt of ponents C, and C, in the product and W, and W., are the peroxymonosulfuric acid and one or more other components respective molecular weights of components C, and C. Con aside from material closely bonded to the salt of peroxy sequently, the ratio R, of the mass fraction (or mass per monosulfuric acid. More particularly, when the salt of per centage) F, of component C, to the mass fraction (or mass oxymonosulfuric acid consists of potassium hydrogen per percentage) F., of component C is: oxymonosulfate provided as a component of potassium monopersulfate triple salt composition, the drug of type II implements the drug of type I for the situation in which the drug of type I is formed with potassium hydrogen peroxy Riba = A. Resi?.) Run(G) (16) monosulfate and one or more components other than the potassium hydrogen Sulfate and the potassium Sulfate in potassium monoperSulfate triple Salt composition. All of the Eq. 16 can be employed to convert mole fraction (or molar) preceding comments about the drug of type I then apply to the ratios into mass fraction ratios and thus into mass fractions. US 2012/0074014 A1 Mar. 29, 2012

0105 Potassium hydrogen peroxymonosulfate as the Sodium Stearate, polyoxyethylene and mixtures thereof), active oxygen-releasing material, sodium chloride as the lubricants (such as magnesium Stearate, polyethylene glycol, inorganic halide, Sodium hexametaphosphate as the alkali and sodium benzoate), stabilizing agents, Solution adjuvants metal phosphate, Sulfamic acid, malic acid as the non-reduc (such as glutamic acid and aspartic acid), water-absorbable ing organic acid, and sodium dodecylbenzene Sulfonate as the materials (such as fumed silica, Sodium carbonate, magne Surfactant are present at the following mass percentages of the sium carbonate, and potassium carbonate) for reducing mois overall material used to form the preceding preferred formu ture, and effervescents (such as cellulose calcium glycolate, lation of the medicinal drug of type I/II: bicarbonate, carbonate, sodium bicarbonate, Sodium carbon 0106 a. Potassium hydrogen peroxymonosulfate— ate, and citric, adipic, and tartaric acids or other similar normally 2-95%, preferably 6-90%, more preferably organic acids) for releasing carbon dioxide to assist with 10-60%, typically 20-25%: effervescence in causing the Solid drug material to disinte 0107 b. Sodium chloride normally 0.001-30%, pref grate. Carbon dioxide and sodium bicarbonate may also assist erably 0.005-7.5%, more preferably 0.01-5%, typically in therapeutic activity. Additionally, dyes, other coloring 0.5-1.5%: agents, flavoring agents, fragrances, corrosion inhibitors, 0.108 c. Sodium hexametaphosphate—normally activity indicators, and organic activators can be applied to 2-60%, preferably 5-45%, more preferably 10-30%, the solid forms of the drug of type I or II. typically 18%; 0115 Semiliquid forms of the medicinal drug of type I or 0109 d. Sulfamic acid normally 1-30%, preferably II include gels, creams, pastes, and ointments. When the drug 1.5-15%, more preferably 3-10%, typically 5-10%: of type I or II is provided in semiliquid form, the drug is 0110 e. Malic acid—normally 0.1-40%, preferably normally dispersed throughout a therapeutically inactive 0.5-30%, more preferably 1-20%, typically 5-10%; and pharmaceutically acceptable carrier, normally a semiliquid 0111 f. sodium dodecylbenzene sulfonate—normally carrier. Although the carrier is normally semiliquid, the drug 1-50%, preferably 7.5-37.5%, more preferably 10-25%, of type I or II can itself be solid, semiliquid, or even liquid if typically 15%. the drug is a suitable Small mass percentage of the carrier. In The remainder of thematerial used to form this formulation of a typical semiliquid form of the drug of type I or II, the drug the medicinal drug of type I/II largely consists of the potas itself consists of solid particles. The semiliquid drug of type I sium hydrogen Sulfate and the potassium sulfate in the potas or II may be provided with various additives such as wetting sium monopersulfate triple salt composition that provides the agents, emulsifying agents, dyes, other coloring agents, fla potassium hydrogen peroxymonosulfate. Voring agents, fragrances, corrosion inhibitors, activity indi 0112 The medicinal drug of type I or II (including the cators, organic activators, stabilizers, and buffering agents. medicinal drug of type I/II) may be provided in Solid, semi 0116. Liquid forms of the medicinal drug of type I or II liquid, or liquid form. The term “semiliquid refers here to include solutions, Suspensions, lotions, emulsions, liniments, matter having properties between a solid and a liquid. The syrups, elixirs, and tinctures. In some cases, the dividing line viscosity of semiliquid matter is sufficiently high that the between liquid and semiliquid forms of the drug of type I or semiliquid matter, when placedona Surface, flows slowly and II is unclear. When the drug of type I or II is provided in liquid does not rapidly adopt the shape of the underlying Surface. form, the drug is typically dispersed throughout a therapeu This contrasts to liquid matter which, when placed on a Sur tically inactive pharmaceutically acceptable liquid carrier. face, readily flows and rapidly adopts the shape of the under Similar to semiliquid forms of the drug of type I or II, the drug lying Surface, typically within a few seconds for up to a itself can be solid, semiliquid, or liquid form. In a typical kilogram of the liquid, and to solid matter which does not liquid form of the drug of type I or II, the drug itself consists flow. As indicated below, a semiliquid form of the drug of type of solid particles dissolved or colloidably suspended in the I or II normally has a dynamic (or absolute) viscosity of carrier. The liquid carrier is normally water (purified and/or 5-5,000 Pa-s at 25° C. distilled) but can be ethanol or a mixture of ethanol and water. 0113 Solid (dry) forms of the medicinal drug of type I or The liquid drug of type I or II may be provided with additives II are powders and tablets (pills) which disintegrate in the Such as wetting agents, Suspending agents, emulsifying body when taken orally. When the drug of type I or II is agents, dyes, other coloring agents, flavoring agents, fra provided in solid form, the drug itself is in solid form and is grances, corrosion inhibitors, activity indicators, organic acti normally dispersed largely throughout a therapeutically inac vators, stabilizing agents (such as sodium Sulfate), and buff tive pharmaceutically acceptable solid carrier. Powder imple ering agents. mentations of the drug of type I or II may be enclosed in 0117. As discussed further below, liquid forms of the water-soluble capsules (Small closed containers such as jack medicinal drug of type I or II can be administered by injection ets, Sachets, films, and the like) which disintegrate in the body or spraying. In addition to water or/and ethanol, the liquid when taken orally. Coating agents (such as Sugar, gelatin, carrier for drug injection may include one or more of veg hydroxypropyl cellulose, and hydroxypropylmethyl cellu etable oil, propylene glycol, polyethylene glycol, Solution lose phthalate) may be variously provided in one or more adjuvants (such as glutamic acid and aspartic acid), and layers or films on the tablets and capsules. The tablets and Soothing agents. The liquid carrier for drug spraying may capsules can be structured to provide metered-release forms include isotonic buffers (such as sodium chloride, Sodium of the drug of type I or II. citrate, and citric acid). 0114. The following materials can be variously admixed 0118. The peroxymonosulfate used informing the medici into solid powder and tablet forms of the medicinal drug of nal drug of type I can be combined with any other component type I or II: Vehicles (such as lactose, mannitol, glucose, of the drug and with a therapeutically inactive pharmaceuti microcrystalline cellulose, and starch) which help deliver the cally acceptable carrier for the drug according to various drug ingredients, binders (such as hydroxypropyl cellulose, techniques. The oxidizing agent, preferably peroxymonosul polyvinylpyrrolidone, magnesium metasilicate aluminate, fate, used in forming the medicinal drug of type II can simi US 2012/0074014 A1 Mar. 29, 2012 larly be combined with the other components of the drug and stance. The powdery drug is then combined with the liquid with a therapeutically inactive pharmaceutically acceptable carrier in Such a manner as to be distributed throughout the carrier for the drug according to various techniques. In the carrier. following description of Such combining techniques for the I0123. The carrier is again a liquid in yet another drug medicinal drugs of types I and II, the term "peroxymonosul fate material' for the drug of type I means both the peroxy formation technique. The peroxymonosulfate material for the monosulfate, when it is provided as Substantially a single salt, medicinal drug of type I is provided in Solid particulate form and a multiple salt composition, such as potassium monop and is mixed into the liquid carrier. If the drug of type I is to erSulfate triple salt composition for potassium hydrogen per be formed with at least one component besides the peroxy oxymonosulfate, which contains the peroxymonosulfate as a monosulfate material, each additional component is provided component. The term “oxidizing agent material” for the drug in solid particulate form or in liquid form. Each additional of type II means both (a) the active oxygen-releasing material component for the drug of type I is then mixed into the liquid when the oxidizing agent is provided as Substantially a single carrier separate from the peroxymonosulfate material. This material and (b) a multi-material composition which contains technique is applicable to the medicinal drug of type II in a the active oxygen-releasing material as a component. When variation in which the oxidizing agent material is again ini the oxidizing agent consists Substantially solely of peroxy tially provided in solid particulate form and in which each monosulfate, the peroxymonosulfate material is the oxidizing other components of the drug initially provided in Solid par agent material. ticulate form or in liquid form. Each additional component for 0119. In one drug formation technique, the carrier, the the drug of type II is mixed into the liquid carrier separate peroxymonosulfate material, and any other component of the from the oxidizing agent material. The mixing for the drug of medicinal drug of type I are initially provided in Solid par type I or II is performed so that the particles of the drug of type ticulate form. This technique is applicable to the medicinal I or II are distributed throughout the carrier. drug of type II in a variation in which the carrier, the oxidizing 0.124 When the carrier is a liquid, the particles of the agent material, and the other components of the drug are peroxymonosulfate material and any other drug component initially provided in solid particulate form. The particles for provided in particulate form for the medicinal drug of type I both the drug of type I and the drug of type II are mixed preferably dissolve in the carrier to form a solution and are together to form a powdery Substance. The mixing is nor thereby distributed substantially uniformly throughout the mally performed so that the particles of the drug are distrib carrier. For the medicinal drug of type II, each drug compo uted largely uniformly throughout the carrier. The drug of nent provided in particulate form preferably dissolves in the type I or II is then available for use as a powder. If desired, the carrier to form a solution and thus is distributed substantially powder can be inserted into water-soluble capsules. uniformly throughout the carrier. 0120 If the medicinal drug of type I or II is to be in solid 0.125. Alternatively, the particles of the peroxymonosul tablet form, the powdery substance is suitably processed to fate material and any other drug component provided in par create solid tablets, including tablets that provide metered ticulate form for the medicinal drug of type I can be sus release forms of the drug after it is administered. The pro pended in the carrier to form a colloid or emulsion. As cessing may include providing the tablets with Suitable coat necessary, the colloid or emulsion is suitably mixed so that the ings. particles of the peroxymonosulfate material and any other 0121 Largely the same procedure can be followed if the drug component provided in particulate form are distributed medicinal drug of type I or II is to be provided in a therapeu substantially uniformly throughout the carrier. For the tically inactive pharmaceutically acceptable semiliquid car medicinal drug of type II, each drug component provided in rier Such as a cream, gel, ointment, or foam except that the particulate form can similarly be suspended in the carrier to powdery Substance is suitable processed to form the semiliq form a colloid or emulsion. As necessary, the colloid or emul uid carrier with the drug particles distributed throughout it. sion is likewise suitably mixed so that the particles of the Alternatively, the carrier can initially be provided in semiliq oxidizing agent material and each other drug component pro uid form with the drug of type I or II furnished in solid vided in particulate form are distributed substantially uni particulate form. If the drug of type I contains at least one formly throughout the carrier. component besides the peroxymonosulfate material, the par I0126. In some of the techniques for combining the peroxy ticles of the drug components are mixed together. Since the monosulfate material and at least one other component of the drug of type II has multiple components, its components are medicinal drug of type I with the carrier, the peroxymonosul simply mixed together. The particles of the drug of type I or II fate may react with another drug component, typically in the are then mixed into the carrier. The mixing for the drug of type carrier. If the drug of type I is to be formed with at least two I or II is normally performed so that the drug particles are components besides the peroxymonosulfate material, two or distributed largely uniformly the semiliquid material of the more of these other components may react with one another, carrier. again typically in the carrier. The peroxymonosulfate or/and 0122. In a further drug formation technique where the any other drug component besides the peroxymonosulfate carrier is to be a liquid and where the medicinal drug of type material may even react with the carrier. The possibility of I is to be formed with at least one component besides the Such reaction(s) is greater when the carrier is a liquid Such as peroxymonosulfate material, the components of the drug are water. As a result, the chemical structure of the final constitu provided in Solid particulate form. This technique is appli ents of the drug of type I may differ from the chemical cable to the medicinal drug of type II in a variation in which structure of the components used to form the drug. Nonethe the oxidizing agent material and other components of the less, the drug of type I can reasonably be described as being drug are initially provided in solid particulate form. The par “formed with the peroxymonosulfate material and each ticles of the components of the drug of type I or II are mixed other indicated component and thus as being “formed at together to form the drug of type I or II as a powdery sub least partially with the peroxymonosulfate. US 2012/0074014 A1 Mar. 29, 2012

0127. As indicated above, the oxidizing agent for the monoxide (CO), Xenon (Xe), OZone (O), nitrogen dioxide medicinal drug of type II is reactable in water, typically (NO), iodine (I), ammonia (NH), water vapor (H2O). aqueous Solution, with the halide to generate halite ions. The or/and hydrocarbons. chemical formula for a hypohalite is XOH (or HOX) where X I0131 The medicinal drug of types I and II is administered represents a halogen Such as fluorine, chlorine, bromine or in various ways to people afflicted with diseases and other iodine. A hypohalite ion thus has the chemical formula XO. debilitating medical conditions caused by bacterial, eukary When the therapeutically inactive pharmaceutically accept otic, prion, and viral pathogens, including fungal, spore able carrier is a water-containing liquid and when the oxidiz caused, and parasitic infections, and by non-pathogenic ing agent and the halide are dissolved in the water or are caused inflammation. In general, the drug of type I or II can be Suspended in colloidal form in the water, hypohalite ions are administered to a person by any procedure or/and route which thereby produced by reaction of the oxidizing agent with the enables the drug to reach the particular location(s) afflicted with the disease to be alleviated by the drug. Depending on halide. Consequently, the chemical structures of Some of the various factor including the nature of the disease, the admin components of the drug of type II in the water-containing istration technique can be global, i.e., systemic, or local and carrier differ from the chemical structures of the correspond thus targeted at the diseased location(s). ing components used to form the drug of type II. However, the 0.132. A topical technique is often used to administer the reaction does not normally cause any significant precipitation medicinal drug of type I or II. As used herein, topical admin of hypohalite material, modified oxidizing agent material, or istration generally means bringing the drug of type I or II into any other material. The drug of type II can reasonably be contact with the outer Surface, typically the skin, of the human described as being “formed with the inorganic halide, sul body and not by introducing the drug into the human body via famic acid, alkali metal phosphate, and the oxidizing agent, one or more major openings, i.e., openings other than pores, and when used, the organic acid and the Surfactant. naturally present along or/and one or more openings artifi 0128. The water for the medicinal drug of type I and II may cially formed along the outer surface of the human body. consist of, or include, any one or more of tap water, drinking Topical administration can be performed by manually bring water, purified water, hypertonic water, hypotonic water, iso ing the drug of type I or II into contact with the body, by tonic water, oxidative reductive potential water, Super-oxi spraying, by immersion (bath or soak), by skin or/and trans dized water, water for injection, Milli-Q water, saline water, dermal patch coated with the drug of type I or II and an heavy water (water containing a higher-than-normal propor adhesive placed on the skin to deliver the drug to the skin or/and through the skin and into the bloodstream, and by other tion of deuterium in the form of deuterium protium oxide or techniques which physically bring the drug into contact with deuterium oxide), light water (water depleted of deuterium), the body. The drug of type I or II can be in solid powderform, and tritiated water (water in which hydrogen is replaced with semiliquid form, or liquid form during topical administration. tritium). Purified water includes deionized water, distilled Topical administration of the drug of type I or II on an eye, water, double distilled water, United States Pharmacopeia typically with the drug in liquid form, can be performed by purified water, laboratory-grade purified water, analytical spraying the drug into the eye, vaporizing the drug into the grade purified water, or/and reagent-grade purified water. The eye, or/and with eye drops. water purification techniques for the drug of type I or II I0133. The medicinal drugs of types I and II can also be include ultra performance liquid chromatography, high per administered non-topically. Non-topical administration, the formance liquid chromatography, distillation, and reverse converse of topical administration, generally here means osmosis. introducing the drug of type I or II into the human body via 0129. The additives, including stabilizers, for the medici one or more major openings naturally present along or/and nal drug of type I and II may include oxidative reductive one or more openings artificially formed along the outer potential water, Super-oxidized water, activity indicators, surface of the human body. Non-topical techniques for adjuvants, anti-adherents, anti-foaming agents, antioxidants, administering the drug of type I or II include oral administra anti-spotting agents, aromas, binders, bioenhancers, buffer tion, intranasal administration, intraotical administration, ing agents, carriers, catalysts, chelating agents, clarifiers, vaginal administration, rectal administration, urethral admin coatings, corrosion inhibitors, deflocculants, diluents, dis istration, and injection alternatively referred to as infusion or persants, distillers, dyes, colorants, pigments, emulsifiers, parenteral administration. enterics, enzymes, excipients, fillers, flavors, flocculants, 0.134 Oral administration is normally done with the foaming agents, glidants, hydrotropes, lubricants, preserva medicinal drug of type I or II in Solid tablet, capsule, or tives, opacifying agents, organic activators, oxygen stabiliz powderform but can be done with the drug in liquid form and ers, preservatives, scale inhibitors, sequestrants, sorbents, sometimes with the drug in semiliquid form. The tablets, solubilizers, Suspending agents, Sweeteners, ultraviolet stabi capsules, and powders may provide metered release of the lizers, vapor barriers, viscosity modifying agents, or/and wet drug of type I or II. For oral administration of the drug of the ting agents. drug of type I or II in liquid or semiliquid form, the drug can 0130 Devices for dispensing, or delivering, the medicinal also be placed in the mouth without having the drug go drug of type I or/and II include, aerosol or/and elevated pres Substantially through the esophagus to the stomach. For Sure containers, atomizers, dry powder inhalers, foggers, mist instance, a liquid form of the drug of type I or II can be sprayers, nebulizers, spray and steam devices, vaporizers, administered orally by spraying the drug into the mouth or by metered-dose inhalers or/and dry powder inhalers. The gases placing the drug in the mouth and then gargling. A powder or or/and propellants used in these dispensing or delivering vapor containing the drug of type I or II can be orally inhaled. devices include nitrogen (N), oxygen (O), argon (Ar), car 0.135 Intranasal administration in which the medicinal bon dioxide (CO), neon (Ne), helium (He), methane (CH), drug of type I or II enters at least one of the nostrils is typically krypton (Kr), hydrogen (H2), nitrous oxide (N2O), carbon done with the drug of type I or II in liquid form. Intranasal US 2012/0074014 A1 Mar. 29, 2012

administration of the drug of type I or II can be performed by drug of type I or II can be combined with metered-release inhalation into a nostril, spraying into a nostril, vaporizing the forms of the drug to obtain desired therapeutic effects. drug into a nostril, with nose drops, or/and by other tech 0.141. The range of administered dosages of the medicinal niques which physically bring the drug into contact with the drug of type I or II varies depending upon the selected route of inside of a nostril. administration, the recipient's characteristics, including age, 0136 Intraotic administration can done with the medici body weight, general state of health, desired therapeutic nal drug of type I or II in Solid powderform, semiliquid form, effect, the duration of the treatment, and the disease or other debilitating medical condition being treated with the drug. and liquid form. In intraotic administration of the drug of type The drug of type I or II can, for example, be separately I or II, the drug typically enters the ear canal. Intraotic admin administered normally 1-12 times per day, preferably 1-8 istration of the drug of type I or II into the ear canal can be times per day, more preferably 1-6 times per day, typically 1-4 performed by manually bringing the drug into contact with times per day, at selected unit dosages or continuously admin the ear canal, by spraying into the ear canal, with ear drops, istered for selected periods at selected rates by suitable con vaporizing the drug into the ear canal, by immersion, or/and tinuous administration techniques. Such as intravenous injec by other techniques which physically bring the drug into tion, to achieve selected total dosage amounts. Unit dosages contact with the ear canal. Spraying can be done with nebu can be combined with metered-release dosages to obtain lizers to achieve selected dosages. Intraotic administration of desired therapeutic effects. the drug of type I or II also includes introducing the drug into 0142. The medicinal drug of type I or II can be adminis the middle ear or/and the inner ear and thus past the eardrum. tered more than 12 times daily depending on the nature of the 0.137 Vaginal and rectal administration can done with the particular disease or other debilitating medical condition medicinal drug of type I or II in Solid powderform, semiliquid being treated with the drug. The concentration of the drug of form, and liquid form. Urethral administration is typically type I or II in its solid, semiliquid, or liquid carrier may exceed done with the drug of type I or II in liquid form. Pessaries, 5% by mass in Some cases. The total administered amount and Suppositories, enemas and the like can be variously employed administration schedule is selected so the drug of type I or II in vaginal, rectal, and urethral administration of the drug of is therapeutically effective in alleviating the symptoms of the type I or II. disease or other debilitating medical condition while being 0138 Administration by injection is typically done with non-toxic or otherwise injurious to the recipient. Addition the medicinal drug of type I or II in liquid form. Types of ally, the drug of type I or II may be used with many other injection administration of the drug of type I or II include medicines and therapies. intravenous, intramuscular, Subcutaneous, intracardiac, intra 0143. The time period during which a person is treated cavernosal, intradermal, intraosseous, intraperitoneal, and with the medicinal drug of type I or II varies depending upon intrathecal injection. the desired therapeutic effect, the particular disease or other 0.139. The concentration of the medicinal drug of type I or debilitating medical condition being treated with the drug, II in its Solid, semiliquid, or liquid carrier is normally and the person's characteristics, including age, body weight, 0.00001-5%, preferably 0.001-3%, more preferably, 0.1-2%. and general state of health. The treatment period is chosen to typically 0.5-1%, by mass. These ranges are particularly be therapeutically effective in alleviating the symptoms of the applicable to the medicinal drug of type I/II for which the disease being treated while avoiding toxicity difficulties with active oxygen-releasing material in the oxidizing agent for the drug of type I or II. The treatment period with the drug of the drug of type II consists Substantially of peroxymonosul type I or II is normally 1 day-12 months, preferably 1 day-6 fate, preferably potassium hydrogen peroxymonosulfate, months, more preferably 1 day-3 months, and typically 1-30 used in forming the drug of type I and for which the material days. Nonetheless, the treatment can extend over multiple used in forming the drug of type I or II includes inorganic years. halide, alkali metal phosphate, and Sulfamic acid. The spe 0144. The treatment plan for the medicinal drug of type I cific concentration is chosen to be therapeutically effective or II can be a one-time treatment, daily treatments, weekly and non-toxic when administered in the ways described treatments, monthly treatments, yearly treatments, or/and a above. long term treatment plan. Depending on the severity of the 0140. The time during which the medicinal drug of type I debilitating condition of the person being treated with the or II is in contact with the area under treatment, especially for drug of type I or II, the treatment plan varies widely as shown topical administration of the drug, varies depending upon the by the examples presented below. Treatment with the drug of selected route of administration, the desired therapeutic type I or II can be used as a preventative measure or/and effect, and the particular disease or other debilitating medical infrequently to maintain a healthy lifestyle. condition being treated with the drug. The time of contact for 0145 The medicinal drug of type I or II is particularly a liquid form of the drug of type I or II is normally 1 minute-12 useful in treating allergic rhinitis, arthritis, bronchitis, hem hours, preferably 1 minute-6 hours, more preferably 1 orrhoids, urticaria, toothache, tinea pedis, acute viral minute-2 hours, typically 1-30 minutes. The time of contact nasopharyngitis, herpes simplex, dandruff, itching, brom for a semiliquid form of the drug of type I or II is normally 1 hidrosis, and vaginitis. The types of arthritis include osteoar minute-12 hours, preferably 1 minute-6 hours, more prefer thritis and gouty arthritis. The drug of type I or II may be used ably 1 minute-2 hours, typically 30 minutes-1 hour. The time to treat many other diseases and otherwise debilitating medi of contact for a solid form of the drug of type I or II is cal conditions. Other uses of the drug of type I or II include normally 1 minute-12 hours, preferably 1 minute-6 hours, uses as an analgesic for treating pain and headaches, as an more preferably 1 minute-2 hours, typically 30 minutes-1 antipyretic for treating fever, as a detoxifying agent for treat hour. The preceding times of contact for liquid, semiliquid, ing hypersensitivity to various drug or/and body reactions, as and Solid forms of the drug of types I and II apply to continu a cutaneous agent for treating debilitating skin conditions, as ous administration of the drug. The time-of-contact of the an hematologic for treating blood diseases and other cardiac US 2012/0074014 A1 Mar. 29, 2012

conditions, as a treatment for genetic or hereditary disorders, thritis without effective relief. The Medicine was provided to as a palliate for reducing conditions, as an idiopathic for the male as a 1% solution for topical administration via com treating unknown causes of a condition, and as an antidote for plete-body immersion (bath) for 15 minutes, with morning preventing or counteracting poisons and other such toxic and night applications, for a minimum of 2 weeks. The male conditions. reported that, after 7 days of treatment, the pain was relieved 0146 Given below are examples of using the medicinal greatly and that, after 14 days of treatment, the pain was very drug of type I/II for treating allergic rhinitis, osteoarthritis, minimal. The male reports that he now uses the Medicine at gouty arthritis, bronchitis, hemorrhoids, urticaria, toothache, tinea pedis, acute viral nasopharyngitis, herpes simplex, dan least twice a week to reduce pain of osteoarthritis. druff, itching, bromhidrosis, and vaginitis. The formulation of the drug of type I/II used in these examples was the pre Example C ferred formulation, mentioned above, in which the drug was formed with potassium hydrogen peroxymonosulfate as the Gouty Arthritis active oxygen-releasing material, sodium chloride as the inorganic halide, Sodium hexametaphosphate as the alkali 0150. A retired adult male had gouty arthritis for 10 years. metal phosphate, Sulfamic acid, malic acid as the non-reduc The male reported that he was in excruciating pain on random ing organic acid, and sodium dodecylbenzene Sulfonate as the days and that previously attempted treatments for the pain Surfactant at approximately the typical mass percentages were unsuccessful. The Medicine was provided to the male as mentioned above. A formulation approximating this formu a 1% solution for topical administration via complete-body lation is commercially available in the product Virkon. This immersion once a day, before bedtime, for a minimum of 20 formulation of the drug of type I/II is referred to below as the minutes for 7 days. The male reported that the pain was “Medicine. greatly relieved on day 4. The male reports that he now sleeps 0147 The Medicine for each person infected with allergic better than in many previous years and that he continues to use rhinitis, osteoarthritis, gouty arthritis, bronchitis, hemor the Medicine at least twice a week as a treatment and preven rhoids, urticaria, toothache, tinea pedis, acute viral nasophar tative. yngitis, herpes simplex, dandruff, itching, bromhidrosis, and vaginitis is provided for topical, intranasal, oral, or/and injec tion administration 1-12 times per day, preferably 1-8 times Example D per day, more preferably 1-6 times per day, typically 1-4 times per day, in liquid format a dosage of 0.00001-5%, preferably Bronchitis 0.001-3%, more preferably 0.1-2%, typically 0.5-1%, for a time of contact of 1 minute-12 hours, preferably 1 minute-6 0151. An adult female had severe coughing and sputum hours, more preferably 1 minute-2 hours, typically 1-30 min due to bronchitis. The female reported that the bronchitis had utes. The treatment period in each in each of the following been intermittent for 10 years and that she had tried many examples is normally 1 12 months, preferably 1-6 months, treatments for her bronchitis and consumed substantial more preferably 1-3 months, typically 1-30 days. amounts of water daily with no success. The Medicine was provided to the female as a 0.1% solution for oral adminis Example A tration by spraying into the mouth 3 times per day at 4-hour Allergic Rhinitis intervals for 7 days. After the 7 days, the female reported that her bronchitis was greatly alleviated, that the urge to cough 0148. A teenage female had allergic rhinitis. The female had diminished greatly, and that the sputum was virtually stated that she experienced annual episodes of itching, burn gone. The female reports that she now feels better than she has ing, congestion, and watering of mucosal membranes appar in the past 10 years. ently resulting from hypersensitivity to plant allergens. The Medicine was provided to the female as a 1% solution for intranasal administration by spraying into the nostrils 3 times Example E a day at 4-hour intervals for 2 weeks. The female reported that her allergic rhinitis symptoms were relieved after 3 days and Hemorrhoids that the symptoms virtually disappeared after 10 days. The female then stopped using the Medicine. The female reported 0152. An adult female had hemorrhoids for over 5 years. that the allergy symptoms returned after 14 more days, that The female stated that the hemorrhoids were so severe as to she resumed taking the Medicine, and that the symptoms prevent her from working, that she was confined to bed during disappeared within several more days. As a preventative mea most of each day due to severe pain in walking and Standing, sure, the female reports that she now uses the Medicine before and that the pain was almost unbearable during bowel move hay fever season. ments. The Medicine was provided to the female as a 1% Solution for rectal/topical administration 1-2 times a day for Example B 14 days. For the rectal/topical administration, the female was Osteoarthritis instructed to perform bowel movements in a container filled with the Medicine to a level so that her buttocks were com 0149. A retired adult male had osteoarthritis for 10 years. pletely immersed in the Medicine, so that the Medicine con The male stated that he was in constant pain throughout the tacted the outer layer of the anus, and so that the Medicine day, thereby limiting his life Substantially to his Surroundings. moved through the anus into the rectum. After each bowel The male reported that he had tried many treatments, such as movement, the Medicine in the container was to be discarded. NSAIDs, glucosamine, and glucocorticoids, for his osteoar The female reported that her hemorrhoids were greatly alle US 2012/0074014 A1 Mar. 29, 2012

viated and that she was now able to walk far distances which reported the she had tried analgesics and herbal remedies to she had not been able to do for over 5 years. treat the cold Sores without complete Success and that she normally ended up waiting about 7 days for the cold sores to Example F scab over. The Medicine was provided to the female as a 1% Solution for topical administration around the mouth at Urticaria 3-hour intervals 4 times a day for 7 days. The female reported 0153. An adult female had a severe outbreak of urticaria that, on day 2, the cold sores had become completely flat with apparently due to consumption of raw seafood. The female the pain and itchiness Substantially gone and that the cold stated that she had itchy and bumpy red spots on her face, back sores were barely visible on day 6. and thighs. The female stated that she had tried many treat ments for her urticaria. The Medicine was provided to the Example K female as a 0.5% solution for topical administration via com plete-body immersion for 20 minutes once a day for a few Dandruff days. The female reported that the itchiness was relieved on 0158 An adult female had dandruff for about 20 years. the night of initial treatment and that her urticaria was virtu The female stated that she avoided wearing black clothes due ally gone on day 3. The female also reported that no previous to the dandruff flaking and that the dandruff caused her to treatment for her urticaria was as fast acting as the Medicine. have low self esteem. The female reported that she had tried numerous treatments, such as Zinc pyrithione, ketoconazole, Example G Selenium sulfide, and many types of herbs, to eliminate her Toothache dandruff and that (some of) these treatments did cause the amount of dandruff to decrease but that dandruff was still 0154 An adult female had a tooth extracted and was in visible on her scalp. The Medicine was provided to the female extreme pain due to the tooth extraction. The Medicine was as a 1% solution for topical administration by scrubbing the provided to the female as a 1% solution for oral administra Medicine into her scalp and hair for 5 minutes and then tion by gargling for 1 minute. The female reported that the washing her scalp and hair. The female reported that she pain diminished greatly in about 30 minutes. The female administered the Medicine to herself in the foregoing manner further reported that she continued using the Medicine before 4 times a week for 2 weeks. After the 2 weeks, the female bedtime that night and the next day during the morning and reported that the dandruff disappeared. The female reports evening and that, after 2 days of treatment, the toothache pain that the dandruff has not come back. disappeared. Example L Example H Itching Tinea Pedis 0159. An adult male had extreme itching for 5 years. The 0155. An adult male had tinea pedis with itching, crack male reported that he had tried many treatments for the itch ing, and burning lesions of his toes. The Medicine was pro ing without success. The Medicine was provided to the male vided to the male as a 1% solution for topical administration as a 1% solution for topical administration via complete-body via foot immersion for 10 minutes a day for several days. The immersion for 20 minutes 2 times a day for 2 weeks. The male male reported that his toes were healed after 5 days and that reported that the itching had diminished by at least 50% on the Medicine was one of the most effective medications that day 3 and that the itching was Substantially gone at the end of he had ever used. the 2 weeks. The male reports that he now uses the Medicine twice a week as an itch preventative. Example I Acute Viral Nasopharyngitis Example M 0156 An adult female apparently had viral nasopharyngi Bromhidrosis tis. She reported the typical viral nasopharyngitis symptoms (0160. An adult male had bromhidrosis in the form of of Sneezing, congestion, and fatigue. The Medicine was pro strong foot odor. The male reported that he tried treatments vided to the female as a 0.1% solution (i) for intranasal such as cologne and deodorant for the bromhidrosis but that administration by spraying and (ii) for oral administration by these treatments caused his skin to swell and redden. The spraying, each type of administration to be performed 3 times Medicine was provided to the male as a 1% solution for a day at 4-hour intervals for 4 days. The female reported that topical administration via footbath immersion for 10 minutes the symptoms of Sneezing, congestion, and restlessness had in the morning and evening for 7 days. After 5 days, the male significantly decreased by day 4 and that they had virtually reported that his foot odor had disappeared. The male further disappeared on the morning of day 5. reported that the foot odor returned about 30 days later, that he then used the Medicine twice in 2 days, and that the foot odor Example J again went away. Herpes Simplex Example N 0157 An adult female had herpes simplex in the form of Vaginitis herpes labialis as indicated by cold sores around her mouth. The female reported that she contracted the cold sores about 0.161. An adult female had vaginitis for 3 years. The 3 times a year, that she felt some pain and itching from the female reported vaginitis symptoms of inflammation, burn cold sores, and that the external visibility of the cold sores ing, itching, and Swelling after intercourse. The female made her reluctant to meet people. The female further reported that she has tried many treatments, such as topical US 2012/0074014 A1 Mar. 29, 2012

antibiotics, anti-fungal creams, and hydrocortisone, for the water, more preferably deionized water. The initial liquid vaginitis but without significant Success. The Medicine was composition thereby has a Suitably high initial potency. The provided to the female as a 1% solution for vaginal/topical Subsequent introduction of the disintegrable composition into administration via vaginal immersion for 10 minutes in the the initial liquid composition converts it into a further liquid morning and evening for 2 weeks. The female reported that composition containing the drug of type I or II. The disinte the burning and itching in the vaginal area were significantly gration characteristics of the disintegrable composition are reduced on day 2 and that the burning, itching and inflamma chosen so that it disintegrates in Such a way in the further tion in the vaginal area were greatly alleviated on day 10. The liquid composition as to provide it with Sufficient active female further reports that she continues to use the Medicine oxygen-containing matter of the drug of type I or II to gen after intercourse. erally compensate for active oxygen lost from the further 0162. A metered-release product in accordance with the composition as time passes. This enables the potency of the invention is a disintegrable composition formed with Solid further liquid composition to be maintained suitably high for material and Suitable for introduction into a liquid, typically an extended period so that the further composition has water. The disintegrable composition consists at least par extended shelf life. tially of active material formed with the medicinal drug of 0166 The ionic purity of a liquid is generally gauged by its type I or II. Immediately prior to being introduced into the conductivity or its resistivity, the inverse of conductivity. The liquid, the disintegrable composition has a mass m of an amount of ionization in the liquid increases as its conductivity initial mass value m. The disintegrable composition is of increases or its resistivity decreases, and vice versa. The Such a structure that the composition gradually disintegrates conductivity of the deionized water (a) into which the disin upon introduction into the liquid for enabling particles of the tegrable composition is introduced in the first embodiment of composition to disperse into the liquid. Mass m, of the slow metered release of the medicinal drug of type I or II and disintegrable composition is 10% to 90% of initial mass value (b) into which the selected amount of the drug of type I or II m, 1 hour to 100 days after the composition is introduced is introduced in the second embodiment of slow metered into the liquid. The rate at which the composition disinte release of the drug of type I or II to form the initial liquid grates is adjusted to accommodate various situations. composition is normally no more than 10 JLS/cm, preferably 0163 Relatively fast metered release, e.g., over a small no more than 1 LS/cm, more preferably no more than 0.1 number of hours to a small number of days, of the medicinal uS/cm, at 25°C. Equivalently, the resistivity of the deionized drug of type I or II is appropriate for some situations such as water at 25°C. is at least 0.2 MS2-cm, preferably at least 1 that in which the disintegrable composition containing the MS2-cm, more preferably at least 10 MS2-cm, (a) prior to drug of type I or II is provided in sufficiently large solid form, introducing the disintegrable composition into the deionized Such as a tablet or a capsule containing a dry powder of the water in the first embodiment of slow metered release and (b) disintegrable composition, foringestion by a person. For Such prior to introducing the selected amount of the drug of type I fast metered release, mass m, of the disintegrable compo or II into the deionized water in the second embodiment of sition is 10% to 90% of initial mass value m, 1 hour to 24 slow metered release. The carrier for the initial liquid com hours after the composition is introduced into the liquid. position can include oxidative reductive potential water Preferably, mass m of the disintegrable composition for or/and Super-oxidized water. fast metered release is 10% to 90% of initial mass value m, 0.167 Metered release of the medicinal drug of type I or II 2 hours to 12 hours after the composition is introduced into at a release rate intermediate to fast and slow metered releases the liquid. In regard to a capsule containing dry powder of the is appropriate for yet other situations. For Such intermediate disintegrable composition, the preceding times begin at the rate metered release, mass m of the disintegrable compo point that the capsule has disintegrated Sufficiently so as to sition is 10% to 90% of initial mass value m, 1 days to 24 expose the active material to the liquid. days after the composition is introduced into the liquid. Pref 0164 Relatively slow metered release, e.g., over multiple erably, mass m, of the disintegrable composition for inter months to a small number of years, of the medicinal drug of mediate-rate metered release is 10% to 90% of initial mass type I or II is appropriate for other situations such as that in value m 5 days to 20 days after the composition is intro which the potency of a liquid form of the drug of type I or II duced into the liquid. The liquid for intermediate-rate is to be maintained Suitably high formultiple months to a year metered release is normally water, preferably high-purity or more. For such slow metered release, mass m, of the water, more preferably deionized water, and can include oxi disintegrable composition is 10% to 90% of initial mass value dative reductive potential water or/and super-oxidized water. m, 25 days to 100 days after the composition is introduced 0.168. The disintegrable composition can, as indicated into the liquid. Preferably, mass m of the disintegrable above, be provided in the form of solid pieces, e.g., tablets, of composition for slow metered release is 10% to 90% of initial significant size, or as a dry powder. The average diameter of mass value m, 45 days to 100 days after the composition is Such solid pieces of significant size is normally at least 10 introduced into the liquid. For slow metered release, the dis mm, preferably 15 mm, more preferably 20 mm. The average integrable composition is generally provided as one or more diameter of the particles of the powder is normally no more Solid pieces, such as tablets, of significant size. The liquid is than 400 um, preferably no more than 300 um, more prefer normally water, preferably high-purity water, more prefer ably no more than 200um. Selected amounts of the powder of ably deionized water, in one embodiment of slow metered the disintegrable composition are commonly respectively release of the drug of type I or II. encased with coatings to form capsules Suitable for introduc 0165. In another embodiment of slow metered release of tion into the liquid. The coatings normally disintegrate rap the medicinal drug of type I or II, the liquid is an initial liquid idly after the capsules are introduced into the liquid. In par composition prepared by dispersing a selected amount of the ticular, the coatings typically disintegrate in several minutes drug of type I or II throughout a therapeutically inactive and thus much faster than the disintegrable composition. The carrier, likewise normally water, preferably high-purity coatings are normally Substantially chemically non-reactive US 2012/0074014 A1 Mar. 29, 2012

with the active material when it is dry or in water. By provid (0173 All of the above-mentioned additional materials, ing the disintegrable composition in the form of Solid mate except possibly the Surfactant, are normally present in each rial, the composition has an extended shelf life. implementation of the disintegrable composition. Candidates 0169. The disintegrable composition is fabricated so as to for the inorganic halide, the metal phosphate, the non-reduc ing acid, and the Surfactant in either implementation of the disintegrate in the manner described above. In this regard, the disintegrable composition and for the oxidizing agent in the disintegrable composition normally includes solid Support implementation using the drug of type II are presented above. material which provides, or assists in providing, the compo 0.174 Preparation of the disintegrable composition entails sition with disintegration characteristics that enable the com providing the active material and any other component of the position to disintegrate in the above-described manner. Con composition in a structure that enables the composition, upon sequently, the Support material is appropriately combined being later introduced into the liquid, to gradually disinte with the active material containing the medicinal drug of type grate in the general metered-release manner specified above. I or II. The support material serves as a solid carrier for the More particularly, the Support material (when present) and active material. the components of the active material are so combined to 0170 The disintegration characteristics can also be con achieve the specified disintegration characteristics. trolled by providing pieces containing the disintegrable com 0.175. The disintegrable composition is administered to a position, whether in tablet form, capsule form, or some other person to treat a debilitating medical condition of the person form, with coatings which partially encase the composition or/and to prevent the person from contracting the debilitating containing pieces and which do not disintegrate significantly medical condition in various ways depending on the nature of in the liquid. For instance, pieces containing the disintegrable the medical condition. In one administration technique, the composition can be readily furnished with partial non-disin person simply ingests one or more pieces, e.g., one or more tegrable coatings that enable the composition to disintegrate tablets or capsules, containing the disintegrable composition. at a relatively constant rate. In addition, the disintegration Liquid, normally water, in the person's body then serves as characteristics can be controlled by providing pieces contain the liquid in which each piece containing the disintegrable ing the disintegrable composition with coatings, partial or composition disintegrates to form a further composition con full, which disintegrate at certain places but not others when taining the medicinal drug of type I or II and thus the active the composition-containing pieces are placed in the liquid. material. 0171 For the situation in which the active material in the 0176). In another administration technique, one or more solid disintegrable composition is implemented with the Solid pieces, e.g., again one or more tablets or capsules, medicinal drug of type I, the active material contains salt of containing the disintegrable composition are introduced into peroxymonosulfuric acid, preferably potassium hydrogen a liquid, again normally water, that serves as a carrier for the peroxymonosulfate. The Support material is normally Sub disintegrable composition. Each solid piece containing the stantially chemically non-reactive with the salt of peroxy disintegrable composition disintegrates in the liquid carrier to monosulfuric acid and with reaction product of the salt of form a further composition, normally liquid, containing the peroxymonosulfuric acid and any other material in this medicinal drug of type I or II and thus again the active mate implementation of the disintegrable composition when it is rial. Material of the further composition is variously admin dry or combined with water. The active material in the imple istered topically, orally, intranasally, intraotically, vaginally, mentation of the disintegrable composition using the drug of rectally, urethrally, and by injection as further described type I may include one or more of inorganic halide, metal above. To the extent that the solid pieces containing the dis phosphate, Sulfamic acid, a non-reducing organic acid, and a integrable composition have not disintegrated, the remaining Surfactant as additional materials. The Support material is portions of the composition-containing pieces are normally then normally substantially chemically non-reactive with not administered to a person. Depending on how fast the each additional material and with reaction product of each disintegration of the disintegrable composition proceeds, the additional material and other material in this implementation disintegration of the composition may take a considerable of the disintegrable composition when it is dry or combined period of time, e.g., hours to days to months, after the first with water. administration of the further composition containing the drug 0172. When the active material in the disintegrable com of type I or II. The potency of the further composition thereby position is implemented with the medicinal drug of type II, stays at a suitably high level for an extended time period. the active material contains inorganic halide an oxidizing 0177. The debilitating medical condition in any of the agent reactable in water with the inorganic halide to generate administration techniques using the disintegrable composi hypohalite ions. The Support material is normally Substan tion can be any of the above-identified debilitating medical tially chemically non-reactive with the oxidizing agent and conditions, namely bacterial, eukaryotic, prion-caused, and with reaction product of the oxidizing agent and other mate viral infections, including fungal, spore-caused, and parasitic rial in this second implementation of the disintegrable com infections, and non-pathogenic-caused inflammation and position when it is dry or combined with water. The active specifically including allergic rhinitis, arthritis, bronchitis, material in the implementation of the disintegrable composi hemorrhoids, urticaria, toothache, tinea pedis, acute viral tion using the drug of type II may include one or more of metal nasopharyngitis, herpes simplex, dandruff, itching, brom phosphate, Sulfamic acid, a non-reducing organic acid, and a hidrosis, and vaginitis. Surfactant as additional materials. The Support material is 0.178 A semiliquid product in accordance with the inven then similarly normally substantially chemically non-reac tion is a semiliquid composition consisting at least of a carrier tive with each additional material and with reaction product and active material dispersed largely throughout the carrier. of each additional material and other material in this second The active material is implemented with the medicinal drug implementation of the disintegrable composition when it is of type I or II. The semiliquid composition normally has a dry or combined with water. dynamic viscosity L of at least 5 Pa-s at 25° C. Dynamic US 2012/0074014 A1 Mar. 29, 2012

Viscosity Lofthe semiliquid composition is preferably at least 0183 The above-mentioned reaction products are vari 10 Pa-s, more preferably at least 20 Pa-s, even more prefer ously present in the semiliquid composition implemented ably at least 50 Pa-s, at 25°C. Additionally, dynamic viscosity with the medicinal drug of type I or II as a result of combining L of the semiliquid composition is normally no more than the drug of type I or II with the carrier. All of these additional 5,000 Pa-s, preferably no more than 2,000 Pa-s, more prefer materials, except possibly the Surfactant, are normally ably no more than 500 Pa-s, even more preferably no more present in each implementation of the semiliquid composi than 150 Pa-s, at 25°C. tion. Candidates for the inorganic halide, the metal phos 0179 The carrier for the semiliquid composition is typi phate, the non-reducing acid, and the Surfactant in either cally semiliquid. However, the carrier can be liquid if the implementation of the semiliquid composition and for the amount of active material present in the carrier is sufficiently oxidizing agent in the implementation using the drug of type high to cause the composition to be semiliquid, i.e., to cause II are presented above. the composition to have the dynamic viscosity characteristics specified above. The carrier often includes water, preferably 0184. It is expected that the semiliquid composition will high-purity water, more preferably deionized water. The car undergo fewer chemical reactions and other physical/chemi rier can include oxidative reductive potential water or/and cal phenomena which cause the potency of the medicinal drug Super-oxidized water. of type I or II in the composition to decrease with time. 0180. The semiliquid composition is prepared by combin Consequently, the shelf life of the semiliquid composition is ing the active material and the carrier so that the active mate expected to be extended. At the same time, the semiliquid rial is dispersed largely throughout the carrier and so that the nature of the composition, especially when Viscosity L of the composition is semiliquid. For instance, the active material composition in the range of 5-5,000 Pa-sat 25°C., enables the can be introduced into the carrier. Alternatively or/and addi composition to be readily administered to humans. tionally, the carrier can be poured on or otherwise placed on 0185. Material of the semiliquid liquid composition is the active material. In either case, Suitable mixing of the administered to a person Sufficiently to treat a debilitating active material and the carrier is typically performed to enable medical condition of the person or/and to prevent the person the active material to be dispersed largely throughout the from contracting the debilitating medical condition. The carrier. administration of material of the semiliquid composition is 0181. The medicinal drug of type I or II may undergo variously performed topically, orally, intranasally, intraoti chemical reactions in the course of combining the active cally, vaginally, rectally, urethrally, and by injection as further material and the carrier. When the active material in the semi described above. The debilitating medical condition can be liquid composition is implemented with the drug of type I, the any of the above-identified debilitating medical conditions, active material contains salt of peroxymonosulfuric acid namely bacterial, eukaryotic, prion-caused, and viral infec or/and reaction product of the salt of peroxymonosulfuric tions, including fungal, spore-caused, and parasitic infec acid and other material of the composition. The salt of per oxymonosulfuric acid preferably is potassium hydrogen per tions, and non-pathogenic-caused inflammation and specifi oxymonosulfate. The active material in the implementation cally including allergic rhinitis, arthritis, bronchitis, using the drug of type I may include one or more of the hemorrhoids, urticaria, toothache, tinea pedis, acute viral following additional materials: (a) inorganic halide or/and nasopharyngitis, herpes simplex, dandruff, itching, brom reaction product of the inorganic halide and other material of hidrosis, and vaginitis. the composition, (b) metal phosphate or/and reaction product 0186 FIG. 1 illustrates a product in accordance with the of the metal phosphate and other material of the composition, invention for dispensing, or delivering, the medicinal drug of (c) sulfamic acid or/and reaction product of sulfamic acid and type I or II provided in a therapeutically inactive liquid carrier other material of the composition, (d) a non-reducing organic for situations in which the liquid form of the drug of type I or acid or/and reaction product of the organic acid and other II needs extended shelflife. In describing the product of FIG. material of the composition, and (e)a surfactant or/and reac 1, all references to the drug of type I or II include any of the tion product of the surfactant and other material of the com variations of the liquid form of drug of type I or II described position. below. 0182. When the active material in the semiliquid compo 0187. The extended-shelf-life product in FIG. 1 is a con sition is implemented with the medicinal drug of type II, the tainer assembly consisting of a container 20, a liquid compo active material contains (a) inorganic halide or/and reaction sition 22, a pressurant gas 24, and a dispenser 26 hermetically product of the inorganic halide and other material of the attached to the top of container 20. Liquid composition 22 and semiliquid composition and (b) the oxidizing agent or/and pressurant gas 24 are situated inside container 20. Pressurant reaction product of the oxidizing agent and other material of gas 24, located above liquid composition 22, exerts an aver the composition where the oxidizing agent is reactable in age internal pressure of more than 1 atm (760 torr), typically water with the inorganic halide to generate hypohalite ions. 2-8 atm, on composition 22. Dispenser 26 controllably dis The active material in the implementation using the drug of penses material of liquid composition 22 from container 20. type II may include one or more of the following additional 0188 Liquid composition 22 includes the therapeutically materials: (a) metal phosphate or/and reaction product of the inactive liquid carrier and active material dispersed largely metal phosphate and other material of the composition, (b) throughout the carrier. The active material consists of the Sulfamic acid or/and reaction product of Sulfamic acid and medicinal drug of type I or II. Pressurant gas 24 consists of a other material of the composition, (c) a non-reducing organic gas which is substantially non-reactive with the drug of type acid or/and reaction product of the organic acid and other I or II and with its carrier. In one embodiment of the container material of the composition, and (d) a Surfactant or/and reac assembly of FIG. 1, liquid composition 22 consists Substan tion product of the surfactant and other material of the com tially solely of the carrier and the active material formed with position. the drug of type I or II. In another embodiment of the con US 2012/0074014 A1 Mar. 29, 2012 20 tainer assembly of FIG. 1, a liquid form of some of the gas reaction product of the organic acid and other material of which forms pressurant gas 24 is also present in liquid com composition 22, and (d) a Surfactant or/and reaction product position 22. of the surfactant and other material of composition 22. 0189 The liquid carrier for the medicinal drug of type I or 0193 The above-mentioned reaction products are vari II in liquid composition 22 is usually water. Certain materials ously present in liquid composition 22 implemented with the in normal water, Such as tap water, can cause the water-carrier medicinal drug of type I or II as a result of combining the drug form of the drug of type I or II to undergo reactions which of type I or II with the liquid carrier. All of the above-men cause the drug's potency to decrease with time. In the con tioned additional materials, except possibly the Surfactant, tainer assembly of FIG. 1, the loss of potency with time is are normally present in each implementation of liquid com reduced by implementing the water carrier for the drug of position 22. Candidates for the inorganic halide, the metal type I or II with high-purity water, preferably deionized water. phosphate, the non-reducing acid, and the Surfactant in either Prior to combining the deionized water and the solid form of implementation of liquid composition 22 and for the oxidiz the drug of type I or II to create the liquid form of the drug of ing agent in the implementation using the drug of type II are type I or II for the container assembly of FIG. 1, the deionized presented above. water has the conductivity and resistivity characteristics men 0194 Visible light and certain other types of radiation, tioned above. The liquid carrier can include oxidative reduc Such as UV radiation, that impinge on the liquid form of the tive potential water or/and super-oxidized water. medicinal drug of type I or II, can also cause the drug's 0190. Ions of material of the medicinal drug of type I or II potency to decrease with time. The potency loss due to inci are inevitably produced when the deionized water and the dent visible light and/or incident UV radiation is reduced by solid form of the drug of type I or II are combined to create the designing container 20 to Substantially block the transmission drug's liquid form. The amount of ionization, per unit Vol of visible light and UV radiation incident on container 20 ume, in the liquid form of the drug of type I or II is therefore from outside container 20. The radiation-transmission block inevitably greater than the amount of ionization, per unit ing can occur by reflection of the incident visible-light and volume, in the deionized water. The conductivity of the liquid UV radiation at the outside surface of container 20 and/or form of the drug of type I or II can be characterized as absorption of the incident radiation by the material of con consisting of (a) a drug-related part arising from ions of tainer 20. As a result, visible light and UV radiation incident material of the drug of type I or II and (b) a water-related part on the outside Surface of container 20 does not significantly arising from other ions in the water carrier. The water-related reach the liquid form of the drug of type I or II inside container part of the conductivity of the liquid form of the drug of type 20 so as to cause the drug's potency to decrease with time. I or II for the container assembly of FIG. 1 is essentially the 0.195 Container 20 is designed to withstand the average conductivity of the deionized waterprior to combining it with internal pressure of more than 1 atm exerted by pressurant gas the solid form of the drug of type I or II. 24. The inside of container is substantially non-reactive with 0191 For the situation in which the active material in liquid composition 22 and thus Substantially non-reactive liquid composition 22 is implemented with the medicinal with the medicinal drug of type I or II and its carrier. The drug of type I, the active material contains salt of peroxy inside of container is also substantially non-reactive with monosulfuric acid or/and reaction product of the salt of per pressurant gas 24. To achieve these capabilities and to achieve oxymonosulfuric acid and other material of composition 22. the desired light-blocking capability, container 20 normally The salt of peroxymonosulfuric acid preferably is potassium consists primarily of Suitably strong metal. Such as steel, hydrogen peroxymonosulfate. The active material in the aluminum, or/and tin, or/and Suitably strong electrical insu implementation of liquid composition 22 using the drug of lating material Such as silica (silicon dioxide) or plastic. If the type I may include one or more of the following additional metal or/and insulating material should react significantly materials: (a) inorganic halide or/and reaction product of the with liquid composition 22 or pressurant gas 24, the metal inorganic halide and other material of composition 22, (b) or/and insulating material can be coated along the inside of metal phosphate or/and reaction product of the metal phos container 20 with material which is substantially non-reactive phate and other material of composition 22, (c) sulfamic acid with composition 22 and pressurant gas 24. or/and reaction product of sulfamic acid and other material of 0196. Visible light and UV radiation incident on the out composition 22, (d) a non-reducing organic acid or/and reac side of container 20 is normally substantially reflected along tion product of the organic acid and other material of compo most of the container's outside surface. If the metal or/and sition 22, and (e)a surfactant or/and reaction product of the insulating material that normally primarily forms container Surfactant and other material of composition 22. 20 is not sufficiently light reflective, the metal or/and insulat 0.192 When the active material in liquid composition 22 is ing material can be coated along the outside of container 20 implemented with the medicinal drug of type II, the active with material which is sufficiently light reflective. The light material contains (a) inorganic halide or/and reaction product reflective material can be coated with light-transparent mate of the inorganic halide and other material of composition 22 rial so that visible light and UV radiation incident on the and (b) the oxidizing agent or/and reaction product of the outside of container 20 largely pass through the transparent oxidizing agent and other material of composition 22. The coating, are reflected by the underlying light-reflective mate oxidizing agent is reactable in water with the inorganic halide rial, and then pass back through the transparent coating. to generate hypohalite ions. The active material in the imple 0.197 Most of container 20 typically appears white or light mentation of liquid composition 22 using the drug of type II colored as seen from outside container 20. In particular, most may include one or more of the following additional materi of the outside of container 20 appears white or light colored als: (a) metal phosphate or/and reaction product of the metal except for dark-colored areas that provide printed informa phosphate and other material of composition 22, (b) Sulfamic tion about the medicinal product of FIG.1. This coloring can, acid or/and reaction product of sulfamic acid and other mate for instance, be achieved by providing container 20 with rial of composition 22, (c) a non-reducing organic acid or/and white or light-colored information-containing labels that US 2012/0074014 A1 Mar. 29, 2012

cover most of the container's outside Surface. Advantage is and sealing element 56 are separately fabricated. Liquid com thereby taken of the phenomenon that objects of light color, position 22 is prepared by Suitably combining the Solid form especially white, are generally more effective in reflecting of the medicinal drug of type I or II and its liquid carrier. If light than are objects of dark color. liquid composition 22 is to include a liquid form of Some of 0198 Container 20 consists of a solid side wall 30, a solid the gas that forms pressurant gas 24, the liquid form of that bottom wall 32 hermetically attached to the bottom of side gas is also Suitably combined with the medicinal drug of type wall 30, and a solid top wall 34 likewise hermetically attached I or II and its liquid carrier. When the liquid carrier for the to side wall 30. Side wall 30 is normally of cylindrical shape, drug of type I or II consists of deionized water, liquid com typically circularly cylindrical shape, but can have other position 22 is prepared by combining the solid form of the shapes. Bottom wall 32 is typically largely flat. Top wall 34 drug of type I or II, its liquid carrier, and, if used in compo typically bulges upward but can be largely flat. The inside sition 22, the liquid form of some of the gas that forms surfaces of walls 30, 32, and 34 contact liquid composition 22 pressurant gas 24 in a vacuum chamber at a chamber pressure and pressurant gas 24. The thicknesses of walls 30, 32, and 34 significantly below atmospheric pressure, nominally 1 atm, in are chosen to be sufficiently great to absorb visible light and order to avoid introducing air and materials in air into com UV radiation incident on any dark areas along the outside of position 22. The chamber pressure is normally no more than container 20 and to safely withstand the internal pressure of 100 torr, preferably no more than 10 torr, more preferably no more than 1 atm, again typically 2-8 atm, exerted by pres more than 1 torr. Surant gas 24. 0204 Container 20, liquid composition 22, dispenser 26, (0199 Dispenser 26 consists of a valve 36 and a dip tube 38 and sealing element 56 are now assembled in Such a manner which extends into liquid composition 22. Valve 36, only that composition 22 and pressurant gas 24 are introduced into generally shown in FIG. 1, is illustrated in more detail in container 20 and in Such a manner that dispenser 26 is her FIGS. 2a and 2b respectively in non-actuated and actuated metically attached to container 20 via sealing element 56. The conditions. The components of valve 36 consist of a valve assembly can be done in various ways depending on various housing 40, a valve spring 42, a spring cup 44, a valve cup 46. factors, including the purity characteristics of liquid compo a sealing gasket 48, a valve stem 50, an actuator 52, and an sition 22. orifice insert 54 configured as shown in FIGS. 2a and 2b. The 0205 If liquid composition 22 needs to be maintained hermetic sealing of dispenser 26 to container 20 is achieved highly pure, e.g., because the liquid carrier for the medicinal with a sealing element 56 situated between valve cup 46 and drug of type I or II consists of deionized water, composition top wall 34. 22 and pressurant gas 24 are introduced into container 20 in 0200 Valve housing 40 is connected to dip tube 38 in Such a way as to Substantially prevent composition 22 from which part of liquid composition 22 is present. The more being contaminated with air and materials in air. Dispenser26 than-1-atm pressure exerted by pressurant gas 24 on liquid is subsequently hermetically attached to container 20 via composition 22 causes material of composition 22 to pass sealing element 56 likewise in Such a way as to Substantially through dip tube 38 and enter valve housing 40. When dis prevent liquid composition 22 from being contaminated with penser 26 is in the non-actuated condition depicted in FIG.2a. air and materials in air. These two operations can, for the top edge of valve cup 44 fully contacts the bottom of instance, be performed in the vacuum chamber directly after sealing gasket 48. This prevents any of liquid composition 22 the operation of preparing liquid composition 22 in the cham from then passing through valve housing 40 and entering ber without removing any of the components of the container valve stem 50. assembly of FIG. 1 from the chamber between any of the 0201 Valve stem 50 has an open area 58 at the bottom of operations. stem 50. Dispenser 26 is actuated by pressing on actuator 52 0206 Dispenser 26 can be hermetically attached to con so that it moves downward. The actuation of dispenser 26 as tainer 20 via sealing element 56 prior to introducing liquid depicted in FIG.2b causes valve cup 44 to move downward composition 22 and pressurant gas 24 into container 20 if and separate from sealing gasket 48. Some of liquid compo composition 22 and gas 24 can be introduced into container sition 22 is then forced upward into valve stem 50 under the 20 via dispenser 26. In that case, the hermetic sealing of driving force provided by the more-than-1-atm pressure of dispenser 26 to container 20 can be performed at atmospheric pressurant gas 24. This part of liquid composition 22 enters a pressure. Liquid composition 22 and pressurant gas 24 are channel 60 in actuator 52 and passes through an orifice 62 in subsequently introduced into container 20 via dispenser 26. If orifice insert 54 to form a spray 64 of composition 22. liquid composition 22 needs to be maintained highly pure, the 0202 Actuator 52 and orifice insert 54 can be alternatively introduction of composition 22 and pressurant gas 24 into configured to enable a stream of liquid composition 22 to be container 20 is performed by placing the partially completed provided form orifice insert. Regardless of whether the con assembly of container 20, dispenser 26, and sealing element tainer assembly of FIG. 1 dispenses liquid composition 22 in 56 in the vacuum chamber, introducing composition 22 into spray-form or stream form, the combination of the configu container 20 via dispenser 26 with the pressure in the chamber ration of dispenser 26 and the dispensing of composition 22 at the above-mentioned below-atmospheric conditions, and under the driving force of the more-than-1-atm pressure of introducing gas 24 into container 20. The introduction of pressurant gas 24 enables dispenser 26 to Substantially pre pressurant gas 24 into container 20 can be performed outside vent air and other material outside container 20 from entering the vacuum chamber. container 20 through dispenser 26. As a result, the potency of 0207. Material of liquid composition 22 is administered to the liquid form of the medicinal drug of type I or II does not a person Sufficiently to treat a debilitating medical condition significantly decrease with time due to reactions with mate of the person or/and to prevent the person from contracting rial outside container 22. the debilitating medical condition. The administration is per 0203 The container assembly of FIG. 1 is manufactured in formed by using dispenser 26 to dispense that material from generally the following manner. Container 20, dispenser 26, the container assembly of FIG. 1 and directing the dispensed US 2012/0074014 A1 Mar. 29, 2012 22 material to the person. The administration of material of active material in powder composition 80 is implemented liquid composition 22 is variously performed topically, with the medicinal drug of type II, the active material contains orally, intranasally, intraotically, vaginally, rectally, ure inorganic halide an oxidizing agent reactable in water with thrally, and by injection as further described above. Injection the inorganic halide to generate hypohalite ions. The active administration can also be used by directing material of liquid material in the implementation of composition 80 using the composition 22 to an injection-administering tool Such as a drug of type II may include one or more of metal phosphate, Syringe. The debilitating medical condition can be any of the Sulfamic acid, a non-reducing organic acid, and a surfactant above-identified debilitating medical conditions, namely as additional materials. All of these additional materials, bacterial, eukaryotic, prion-caused, and viral infections, except possibly the Surfactant, are normally present in each including fungal, spore-caused, and parasitic infections, and implementation of powder composition 80. Candidates for non-pathogenic-caused inflammation, again specifically the inorganic halide, the metal phosphate, the non-reducing including allergic rhinitis, arthritis, bronchitis, hemorrhoids, acid, and the Surfactant in either implementation of compo urticaria, toothache, tinea pedis, acute viral nasopharyngitis, sition 80 and for the oxidizing agent in the implementation herpes simplex, dandruff, itching, bromhidrosis, and vagini using the drug of type II are presented above. tis. 0212. The double-container assembly of FIG. 3 is manu 0208 Another product in accordance with the invention is factured in generally the following way. Dispenser 74, the a double-container assembly as illustrated in FIG. 3 for con container unit consisting of containers 70 and 72, and powder trollably dispensing, or delivering, a liquid form of the composition 80 are separately fabricated. The container unit medicinal drug of type I or II. The hardware components of is manufactured so that each of containers 70 and 72 has an the double-container assembly of FIG.3 consist of a hermeti opening. If the double-container assembly is provided to a cally sealed first container 70, a second container 72, and a user as a single unit, dispenser 74 is attached to container 72, dispenser 74. Containers 70 and 72 form a container unit preferably in a hermetic manner. Liquid carrier 78 is sepa sharing a common breakable wall 76 which is designed to be rately provided. broken by a user without significantly otherwise damaging 0213 Regardless of whether the double-container assem the structural integrity of the double-container assembly. bly of FIG.3 is provided to a user as a single unit or dispenser Container 70 contains a therapeutically inactive liquid carrier 74 is provided to a user as a separate unit from the container 78, normally water for the drug of type I or II. The water for unit formed with containers 70 and 72, liquid carrier 78 is liquid carrier 78 can be high-purity water such as deionized introduced into container 70 via its opening. The opening in water and can include oxidative reductive potential water container 70 is then closed and hermetically sealed. Powder or/and Super-oxidized water. Container 72 contains a primary composition 80, which is created by combining powders of powder composition 80 consisting at least partially of active the components of the medicinal drug of type I or II, is material formed with the drug of type I or II. similarly introduced into container 72 via its opening. The 0209 Dispenser 74 consists of an inlet port 82, a valve 84, opening in container 72 is similarly closed and sealed, pref and an outlet port 86. Inlet port 82 is attached to, or integral erably hermetically, to complete the fabrication process. The with, one of containers 70 and 72 at a location spaced apart introduction of powder composition 80 into container 72 and from breakable wall 76. In the example of FIG.3, inlet port82 the closure of its opening can be performed before or after is integral with, or attached to, container 72 that contains introducing liquid carrier 78 into container 70 and closing its powder composition 80. Valve 84 controllably connects inlet opening. port 82 and outlet port 86 so that material can move through 0214. A user uses the double-container assembly of FIG.3 dispenser 74 when valve 84 is at least partially open and is in the following way. If dispenser 74 is provided to a user as Substantially prevented from moving through dispenser 74 a separate unit from the container unit formed with containers when valve 84 is closed. 70 and 72, the user attaches dispenser 74 to container 72. 0210. The double-container assembly of FIG. 3 can be Regardless of whether the double-container assembly is pro provided to a user as a single unit in which dispenser 76 is vided to the user as a single unit or dispenser 74 is provided to attached to, or integral with, one of containers 70 and 72 as a the user as a separate unit from the container unit formed with result of inlet port 82 being attached to, or integral with, one containers 70 and 72, the user now breaks common wall 76 by of containers 70 and 72 so that. Alternatively, dispenser 74 Suitably pressing on wall 76 to form one or more openings in can be provided to a user as a separate unit from containers 70 wall 76 without significantly otherwise damaging the struc and 72. In that case, dispenser 74 is configured so as to be tural integrity of the double-container assembly. The break Suitable for attachment to container 72 containing powder age of wall 76 enables the respective internal volumes of composition80. More particularly, container 72 normally has containers 70 and 72 to be connected together. Liquid carrier a location specifically configured to receive inlet port 82. 78 and powder composition 80 thereby combine to form a Connection of dispenser 74 to container 72 in this alternative further liquid composition containing the medicinal drug of is preferably done shortly before dispensing any of the liquid type I or II. The user typically shakes the double-container form of the medicinal drug of type I or II from the double assembly so as to mix powder composition 80 into liquid container assembly of FIG. 3. carrier 78 so that the active material is dispersed largely 0211 When the active material in powder composition 80 throughout carrier 78. is implemented with the medicinal drug of type I, the active 0215 Material of the further liquid composition contain material contains salt of peroxymonosulfuric acid, preferably ing the medicinal drug of type I or II in the double-container potassium hydrogen peroxymonosulfate. The active material assembly of FIG. 3 is administered to a person sufficiently to in the implementation of composition 80 using the drug of treat a debilitating medical condition of the person or/and to type I may include one or more of inorganic halide, metal prevent the person from contracting the debilitating medical phosphate, Sulfamic acid, a non-reducing organic acid, and a condition. The administration is performed by using dis Surfactant as additional materials. In the situation where the penser 74 to dispensing that material from the double-con US 2012/0074014 A1 Mar. 29, 2012

tainer assembly and directing the dispensed material to the additional material and other material in this implementation person. Material of the further liquid composition is variously of the powder composition when it is dry or combined with administered topically, orally, intranasally, intraotically, Water. vaginally, rectally, and urethrally as further described above. 0220. In another implementation of the powder composi Injection administration can also be used by directing mate tion, the active material in solid particles 90 consists of the rial of the further liquid composition to an injection-admin medicinal drug of type II. Taking note that the drug of type II istering tool such as a Syringe. The debilitating medical con includes inorganic halide and an oxidizing agent reactable in dition can again be any of the above-identified debilitating water with the inorganic halide to generate hypohalite ions, medical conditions, namely bacterial, eukaryotic, prion the drug of type II is present at a sufficiently low concentra tion in particles 90 of this second implementation of the caused, and viral infections, including fungal, spore-caused, powder composition due similarly to the presence of the and parasitic infections, and non-pathogenic-caused inflam particle Support material that the average mass percentage of mation and specifically including allergic rhinitis, arthritis, the oxidizing agent in particles 90 is no more than 10%, bronchitis, hemorrhoids, urticaria, toothache, tinea pedis, preferably no more than 5%, more preferably no more than acute viral nasopharyngitis, herpes simplex, dandruff, itch 2%, even more preferably no more than 1%. In other words, ing, bromhidrosis, and vaginitis. the mass of the oxidizing agent is no more than 10%, prefer 0216) Importantly, powder composition 80 has a long ably no more than 5%, more preferably no more than 2%, shelf life. The further liquid composition need not be formed even more preferably no more than 1%, of the mass of par from liquid carrier 78 and powder composition 80 until ticles 90. The support material is normally substantially shortly before the further liquid composition is administered chemically non-reactive with the oxidizing agent and with to a person. This enables the double-container assembly of reaction product of the oxidizing agent and other material in FIG. 3 to have a long shelf life. the second implementation of the powder composition when 0217. A further product in accordance with the invention it is dry or combined with water. is a powder composition formed with solid particles 90 as 0221) The active material in particles 90 of the powder generally depicted in FIG. 4. Solid particles 90 are illustrated containing the medicinal drug of type II may include one or in FIG. 4 as overlying a surface 92 which can, for example, be more of metal phosphate, Sulfamic acid, a non-reducing organic acid, and a Surfactant as additional materials. The the bottom of a container (not shown). The shapes of particles Support material is then similarly normally Substantially 90 can be generally the same or can vary significantly. For chemically non-reactive with each additional material and instance, particles 90 can be of generally random shapes. The with reaction product of each additional material and other sizes of particles 90 can also vary significantly. Particles 90 material in the second implementation of the powder compo consist of Solid active material and solid particle Support sition when it is dry or combined with water. material which enables particles 90 to achieve the concentra 0222 All of the preceding additional materials, except tion characteristics described below and which serves as a possibly the Surfactant, are normally present in each imple solid carrier for the active material. Because particles 90 mentation of the powder composition formed with solid par consist of solid material, the powder composition of FIG. 4 ticles 90. Candidates for the inorganic halide, the metal phos has a long shelf life. phate, the non-reducing acid, and the Surfactant in either 0218. The active material in solid particles 90 consists of implementation of the powder composition and for the oxi the medicinal drug of type I in one implementation of the dizing agent in the implementation using the medicinal drug powder composition. The active material in this implementa of type II are presented above. tion of the powder composition thereby includes salt of per 0223) The average diameter of particles 90 of the powder oxymonosulfuric acid, preferably potassium hydrogen per containing the medicinal drug of type I or II is normally no oxymonosulfate. The drug of type I is presentata Sufficiently more than 500 um, preferably no more than 400 um, more low concentration in particles 90 in this implementation of the preferably no more than 300 lum. The average diameter of powder composition due to the presence of the particle Sup these powder particles is normally at least 50 um, preferably port material that the average mass percentage of the salt of at least 100 um, more preferably at least 150 lum. peroxymonosulfuric acid in particles 90 is no more than 10%, 0224. The particle-containing composition is prepared in preferably no more than 5%, more preferably no more than the following manner. The active material and the particle 2%, even more preferably no more than 1%. That is, the mass support material are combined to form solid particles 90. This of the salt of peroxymonosulfuric acid is no more than 10%, may involve combining the active material and the Support preferably no more than 5%, more preferably no more than material to form one or more relatively large Solid pieces of 2%, even more preferably no more than 1%, of the mass of material composed of the active and Support materials and particles 90. The support material is normally substantially then cutting each Such large solid piece up to form particles chemically non-reactive with the salt of peroxymonosulfuric 90. acid and with reaction product of the salt of peroxymonosul 0225. Solid particles 90 are combined with a therapeuti furic acid and any other material in this implementation of the cally inactive liquid carrier, normally water, to produce a powder composition when it is dry or combined with water. further medicinal composition as a liquid or semiliquid form 0219. The active material in particles 90 in the implemen of the medicinal drug of type I or II. The liquid carrier can be tation of the powder composition containing the medicinal high-purity water Such as deionized water and can include drug of type I may include one or more of inorganic halide, oxidative reductive potential water or/and super-oxidized metal phosphate, Sulfamic acid, a non-reducing organic acid, water. The support material in particles 90 is normally sub and a Surfactant as additional materials. The Support material stantially chemically non-reactive with the carrier. Whether is then normally substantially chemically non-reactive with the further medicinal composition is a liquid or a semiliquid each additional material and with reaction product of each depends primarily on the dynamic viscosity g. The further US 2012/0074014 A1 Mar. 29, 2012 24 medicinal composition is typically deemed a liquid when and with reaction products of the components of the drug of dynamic viscosity g of the composition is less than 5 Pa-S at type I or II when the powder containing the drug of type I or 25°C. and as a semiliquid when Viscosity g of the composi II is dry or introduced into water. In cases where the carrier tion is at least 5 Pa-s at 25°C. does not consist of water, the particle Support material and the 0226 Combining solid particles 90 and the liquid carrier carrier can be chosen so that the particle Support material is can be performed by introducing particles 90 into the carrier. Substantially chemically non-reactive with the components of Alternatively or/and additionally, the carrier can be poured or the medicinal drug of type I or II and with reaction products otherwise placed on particles 90. In any event, particles 90 of the components of the drug of type I or II when the powder disintegrate in the carrier. The material of particles 90 typi containing the drug of type I or II is dry or introduced into the cally dissolves in the carrier to form a solution. carrier. However, the liquid nature of the carrier, especially 0227. The medicinal drug of type I or II may undergo when it consists of water, promotes chemical reactions among chemical reactions in the course of combining Solid particles the components of the drug of type I or II and between the 90 and the liquid carrier. The active material is thereby con components of the drug of type I or II and the carrier. verted into further active material dispersed largely through 0233. Utilizing the particle support material and the liquid out the carrier. These chemical reactions cause the further carrier in accordance with the formulation ranges presented active material to differ from the original active material in above effectively replaces some of the carrier with the particle particles 90. Support material. Since the liquid carrier promotes chemical 0228. In the implementation of the powder composition reactions involving the components of the medicinal drug of where solid particles 90 contain the medicinal drug of type I type I or II and since the particle Support material and the and thus contain salt of peroxymonosulfuric acid, the further carrier can be chosen so that the particle Support material is active material includes the salt of peroxymonosulfuric acid Substantially chemically non-reactive in dry form and in the or/and reaction product of the salt of peroxymonosulfuric presence of the carrier, the result of so replacing some of the acid and other material of the powder composition containing carrier with the particle support material is to produce fewer the drug of type I. When particles 90 containing the drug of chemical reactions in the further medicinal composition type I include one or more of inorganic halide, metal phos formed by combining solid particles 90 and the carrier than in phate, Sulfamic acid, a non-reducing organic acid, and a Sur the above-mentioned liquid medicinal composition formed factant as additional materials, the further active material also by combining the drug of type I or II with a water carrier. The includes each such additional material or/and reaction prod incidence of physical/chemical phenomena which cause the uct of that additional material and other material of the pow potency of the drug of type I or II in the further composition der composition containing the drug of type I. to decrease with time is therefore expected to decrease. The 0229. The liquid carrier and particles 90 containing the further medicinal composition is therefore expected to main medicinal drug of type I are combined at a percentage ratio of tain its potency at an adequate level for increased time. no more than 10% by mass, preferably no more than 5% by 0234. Material of the further liquid or semiliquid medici mass, more preferably no more than 2% by mass, of the salt of nal composition formed by combining solid particles 90 and peroxymonosulfuric acid to the carrier. That is, the mass of the liquid carrier is administered to a person Sufficiently to the salt of peroxymonosulfuric acid is no more than 10%, treat a debilitating medical condition of the person or/and to preferably no more than 5%, more preferably no more than prevent the person from contracting the debilitating medical 2%, of the mass of the liquid carrier. condition. The administration of material of the further liquid 0230. In the implementation of the powder composition or semiliquid composition is variously performed topically, where solid particles 90 contain the medicinal drug of type II orally, intranasally, intraotically, vaginally, rectally, ure and therefore an oxidizing agent and inorganic halide, the thrally, and by injection as further described above depending further active material includes the oxidizing agentor/and (ii) on whether the further medicinal composition is a liquid or a reaction product of the oxidizing agent and other material of semiliquid. The debilitating medical condition can once again the powder composition containing the drug of type II. When be any of the above-identified debilitating medical condi particles 90 containing the drug of type II include one or more tions, namely bacterial, eukaryotic, prion-caused, and viral of metal phosphate, Sulfamic acid, a non-reducing organic infections, including fungal, spore-caused, and parasitic acid, and a Surfactant as additional materials, the further infections, and non-pathogenic-caused inflammation and active material also includes each Such additional material specifically including allergic rhinitis, arthritis, bronchitis, or/and reaction product of that additional material and other hemorrhoids, urticaria, toothache, tinea pedis, acute viral material of the powder composition containing the drug of nasopharyngitis, herpes simplex, dandruff, itching, brom type II. hidrosis, and vaginitis. 0231. The liquid carrier and particles 90 containing the 0235 Another product in accordance with the invention is medicinal drug of type II are combined at a percentage ratio of a composition containing a liquid carrier, active material dis no more than 10% by mass, preferably no more than 5% by persed largely throughout the carrier, and an inhibitor dis mass, more preferably no more than 2% by mass, of the persed largely throughout the liquid carrier. The active mate oxidizing agent to the carrier. In other words, the mass of the rial in the inhibitor-containing composition consists of the oxidizing agent is no more than 10%, preferably no more than medicinal drug of type I or II. More specifically, the active 5%, more preferably no more than 2%, of the mass of the material includes an oxidizing agent or/and reaction product liquid carrier. of the oxidizing agent and other material of the composition. 0232. The support material in solid particles 90 is, as indi The oxidizing agent contains active oxygen consisting of cated above, normally Substantially chemically non-reactive chemically readily transferable oxygen atoms. Each mol with the liquid carrier. The particle Support material is, as also ecule of the oxidizing agent has at least one atom of active indicated above, normally Substantially chemically non-reac oxygen. The inhibitor inhibits the composition from losing tive with the components of the medicinal drug of type I or II active oxygen. This enables the potency of the inhibitor US 2012/0074014 A1 Mar. 29, 2012 containing composition to be maintained at a suitably high containing composition and for the oxidizing agent in the level for an extended time so that the composition has implementation using the drug of type II are presented above. increased shelf life. 0240. The inhibitor-containing composition is prepared 0236. The capability of the inhibitor to prevent active oxy by combining the active material, the liquid carrier, and the gen from being lost from the inhibitor-containing composi inhibitor so that the active material and the inhibitor are tion is described with reference to a comparative composition dispersed largely throughout the carrier. For example, the which lacks the inhibitor but is otherwise constituted the same active material and the inhibitor can be introduced into the as the inhibitor-containing composition. The inhibitor causes carrier. Alternatively or/and additionally, the carrier can be the loss of active oxygen from the inhibitor-containing com poured on or otherwise placed on the active material or/and position to be at least 10% lower, preferably at least 20% the inhibitor. In either case, suitable mixing of the active lower, more preferably at least 30% lower, as a function of material, the inhibitor, and the carrier is typically performed time than what would arise in the comparative composition to enable the active material and the inhibitor to be dispersed up to the point at which the comparative composition has lost largely throughout the carrier. 50% of its active oxygen. 0241 Water, preferably deionized water, normally serves 0237 When the active material in the inhibitor-containing as the liquid carrier in the inhibitor-containing composition. composition is implemented with the medicinal drug of type For the preferred case in which the liquid carrier consists of I, the active material contains salt of peroxymonosulfuric acid deionized water, the deionized water has the above-men or/and reaction product of the salt of peroxymonosulfuric tioned conductivity and resistivity characteristics prior to acid and other material of the composition. The salt of per combining the deionized water, the active material, and the oxymonosulfuric acid preferably is potassium hydrogen per inhibitor to form the inhibitor-containing composition. The oxymonosulfate. Each molecule of the salt of peroxymono liquid carrier can include oxidative reductive potential water Sulfuric acid has one atom of active oxygen for each single or/and Super-oxidized water. oxygen-oxygen bond in the molecule and thus one atom of 0242. Material of the inhibitor-containing composition is active oxygen for each SOs group in the molecule. The active administered to a person Sufficiently to treat a debilitating material in the implementation of the inhibitor-containing medical condition of the person or/and to prevent the person composition using the drug of type I may include one or more from contracting the debilitating medical condition. The of the following additional materials: (a) inorganic halide administration of material of the inhibitor-containing compo or/and reaction product of the inorganic halide and other sition is variously performed topically, orally, intranasally, material of the composition, (b) metal phosphate or/and reac intraotically, vaginally, rectally, urethrally, and by injection as tion product of the metal phosphate and other material of the further described above. The debilitating medical condition composition, (c) sulfamic acid or/and reaction product of can again be any of the above-identified debilitating medical Sulfamic acid and other material of the composition, (d) a conditions, namely bacterial, eukaryotic, prion-caused, and non-reducing organic acid or/and reaction product of the viral infections, including fungal, spore-caused, and parasitic organic acid and other material of the composition, and (e) a infections, and non-pathogenic-caused inflammation and Surfactant or/and reaction product of the Surfactant and other specifically including allergic rhinitis, arthritis, bronchitis, material of the composition. hemorrhoids, urticaria, toothache, tinea pedis, acute viral 0238. In the situation where the active material in the nasopharyngitis, herpes simplex, dandruff, itching, brom inhibitor-containing composition is implemented with the hidrosis, and vaginitis. medicinal drug of type II, the liquid carrier consists of water, 0243 While the invention has been described with refer and the active material contains inorganic halide or/and reac ence to preferred embodiments, this description is solely for tion product of the inorganic halide and other material of the the purpose of illustration and is not to be construed as lim composition in addition to the oxidizing agentor/and reaction iting the scope of the invention claimed below. For instance, product of the oxidizing agent and other material of the com the disintegrable composition containing active material position. The oxidizing agent is reactable in water with the formed with the medicinal drug of type I or II need not be fully inorganic halide to generate hypohalite ions. The active mate Solid provided that pieces of the disintegrable composition rial in the implementation of the inhibitor-containing compo Substantially maintain their shape as time passes prior to sition using the drug of type II may include one or more of the introduction of the composition into the liquid in which the following additional materials: (a) metal phosphate or/and composition disintegrates. More particularly, the disinte reaction product of the metal phosphate and other material of grable composition can be a highly viscous semiliquid, e.g., a the composition, (b) sulfamic acid or/and reaction product of semiliquid of similar dynamic viscosity to that of glass. Sulfamic acid and other material of the composition, (c) a 0244 Instead of having common wall 76 in the double non-reducing organic acid or/and reaction product of the container assembly of FIG. 3 be breakable, dispenser 74 can organic acid and other material of the composition, and (d) a be modified to have inlet ports connected to both of containers Surfactant or/and reaction product of the Surfactant and other 70 and 72 so that matter of liquid carrier 78 and powder material of the composition. composition 80 separately enter dispenser 74. Containers 70 0239. The above-mentioned reaction products are vari and 72 can even be physically separate from each other. ously present in the inhibitor-containing composition imple Container 70 that contains liquid carrier 78 can be configured mented with the medicinal drug of type I or II due to com in the same way as container 20 in the container assembly of bining the drug of type I or II with the liquid carrier. All of the FIG. 1. In any event, dispenser 74 is also modified so as to above-mentioned additional materials, except possibly the combine the incoming matters of liquid carrier 78 and powder Surfactant, are normally present in each implementation of composition 80 by Suitably mixing that incoming material to the inhibitor-containing composition. Candidates for the produce the liquid composition provided from outlet port86. inorganic halide, the metal phosphate, the non-reducing acid, As in the double-container assembly of FIG. 3, the further and the surfactant in either implementation of the inhibitor liquid composition need not be formed from liquid carrier 78 US 2012/0074014 A1 Mar. 29, 2012 26 and powder composition 80 until shortly before the further that occur in the circulatory, digestive, excretory, reproduc liquid composition is administered to a person. This variation tive, and respiratory systems, and (h3) the skeletal muscles of the double-container assembly of FIG. 3 likewise has a which are attached to the bones and enable voluntary move long shelf life. ment of limbs. 0245. The above-mentioned oxidizing agents which 0247 Such other debilitating human health conditions release oxygen may be replaced, in forming variations of may, for example, further include medical conditions dealing some embodiments of the medicinal drug of type II, with with (i) the musculoskeletal system in which the skeleton, oxidizing agents which do not release oxygen but which muscles, bones, cartilage, joints, ligaments, tendons, and accept electrons in reduction-oxidization chemical reactions associated tissues provide movements to the body and main at oxidizing strength roughly equivalent to the oxidizing tain its structural form, () the nervous system in which the agents which release oxygen. The products of the invention bodily system of cells, neurons, tissues, and organs regulates can be used to treat non-human animals variously inflicted (collects, transfers, and processes) the body's function to with diseases and other debilitating medical conditions caused by bacterial, eukaryotic, prion, and viral pathogens, internal and external stimuli and transmits impulses to the including fungal, spore, and parasitic pathogens, and non effector organs and also regulates secretions of the endocrine pathogenic inflammation. The products of the invention can system by the action of neurohormones and which includes be used to prevent non-human animals from contracting Such the brain, spinal cord, peripheral and autonomic nerves, debilitating medical conditions. nerves, ganglia, parts of the receptor organs, parts of the 0246. In addition to Successfully treating, and preventing effector organs, and the sensory organs Such as the ears and the occurrence of allergic rhinitis, arthritis, bronchitis, hem eyes, (k) the reproductive system in which organs and parts orrhoids, urticaria, toothache, tinea pedis, acute viral function in reproduction, the female includes, ovaries, fallo nasopharyngitis, herpes simplex, dandruff, itching, brom pian tubes, uterus, cervix, Vagina, Vulva, and also the mam hidrosis, and vaginitis in humans, the products of the inven mary glands, and in the male includes, seminal vesicles, pros tion can be used to treat or/and prevent many other debilitat tate, urethra, Vas deferens, testes, and penis, (1) the respiratory ing human health conditions. Such other debilitating human system which is involved in the intake and exchange of oxy health conditions may, for example, include medical condi gen and carbon dioxide between the body and the environ tions dealing with (a) the circulatory and cardiovascular sys ment and which includes the nose, nasal passages, pharynx, tem involved in pumping and circulating blood through the larynx, trachea, bronchi, heart, ribs, diaphragm, and lungs, body in its organs and tissues, including blood vessels, arter (m) the skeletal system formed with bones, cartilage, joints, ies, capillaries, heart, and veins, (b) the digestive or gas tendons, and other connective tissues which protect and Sup trointestinal system involved in the ingestion and digestion of port the body tissues, internal organs and produces blood cells food with orthrough the salivary glands, esophagus, stomach, and stores minerals, (n) the urinary system which is formed liver, gallbladder, pancreas, appendix, intestines, rectum, and with the kidneys, ureters, bladder, and urethra of the urinary anus, (c) the endocrine system which chemically controls tract and which is involved in the regulation of water content various functions of cells, tissues, and organs through the and electrolyte concentration through the excretion of meta secretion of hormones made by endocrine glands, such as the bolic wastes, excess water, and electrolytes in the form of hypothalamus, pituitary, pineal, thyroid, parathyroid, and urine, and (o) the vestibular system which is involved with the adrenal gland as well as the islets of Langerhans, ovaries, equilibrium and organs mediating the labyrinthine sense and pancreas, and testes, (d) the integumentary system consisting which includes the anterior canal, utricle, Saccule, nerve, of the skin and its related Structures, the hair, nails, Sweat cochlea, horizontal canal, and posterior canal. glands, and sebaceous glands, (e) the endocannabinoid sys 0248 More specifically, the products of the invention may tem in which the neuromodulatory lipids and receptors be used to treator/and prevent (i) bronchial asthma, (ii) tuber involve a variety of physiological processes of the brain, culosis, (iii) cholera, (iv) syphilis, (v) meningitis, (vi) pneu including, appetite, cognition, emotional responses, homeo monia, (vii) sepsis, (viii) cystic fibrosis, (ix) aspergillosis, (X) Stasis, motor learning, pain-sensation, and synaptic plasticity, psoriasis, (xi) aspergilloma, (xii) amoebiasis, (xiii) Lyme dis (f) the immune system which neutralizes pathogenic organ ease, (xiv) malaria, (XV) prion infectious diseases including isms or/and foreign matter and which includes organs, such as transmissible spongiform encephalopathic diseases Such as the skin and mucous membranes, adenoids, antibody produc Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker ers, leukocytes, lymph nodes, and lymphoid tissue (as in the syndrome, fatal familial insomnia, and kuru, (Xvi) Alpers gastrointestinal tract and bone marrow), lymphocytes includ syndrome, (xvii) AIDS, (xviii) hepatitides including hepatitis ing B cells and T cells, stem cells, spleen, thymus, and tonsils, A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. (xix) (g) the lymphatic system which is involved in the circulation cancers including carcinoma, sarcoma, leukemia, lymphoma, of lymph between the cells, tissues, and organs to the blood germ cell tumors, and blastic tumors, (XX) heart diseases and stream and which includes tonsils, thymus, spleen, lymph, conditions including arrhythmias, cardiomyopathies, cardio lymph nodes, lymphatic vessels, lymphocytes, sinuses vascular diseases, congenital heart defects, heart infections, through which lymph is carried, lymphoid tissues, and bone and valvular heart diseases, (XXi) hypercholesterolemia, marrow where stem cells differentiate into precursors of B (XXii) hypertriglyceridemia, (XXiii) atherosclerosis, (XXiv) cells and T cells, and (h) the muscular system formed with diabetes mellitus including diabetes type 1, diabetes type 2, muscle cells and tissues that brings about movement of gestational diabetes, congenital diabetes, cystic fibrosis-re organs, other body parts, maintenance of posture, and heat lated diabetes, steroid diabetes, and forms of monogenic dia production. The muscular system includes three basic kinds betes, (XXV) ocular disorders including conjunctivitis, tra of muscles, namely (hl) the cardiac muscles which form the choma, and uveitis, (XXVi) ear disorders including Meniere's walls of the heart, (h2) the smooth muscles which are found in disease, tinnitus, and otitis media, and (XXVii) urethral disor the internal organs and assist in the involuntary movements ders including urethral stricture and urethritis. US 2012/0074014 A1 Mar. 29, 2012 27

0249 Furthermore, the products of the invention may be protists in the group of bikonts including apusozoa, archae used to treat or/and prevent (i) blast wounds, (ii) dermatitis plastida, excavata, centrohelida, chromalveolata, and including contact dermatitis, atopic dermatitis, dermatitis rhizaria, (v) protists in the group of unikontaincluding amoe herpetiformis, Seborrheic dermatitis, nummular dermatitis, bozoa and opisthokonta, and (vi) the metazoa group including and Stasis dermatitis, (iii) diabetic ulcers, (iv) gastroenteritis, eumetazoa, placozoa, and porifera. (v) helminthiasis including soil-transmitted helminthes, 0254 The products of the invention may be used to treat ancylostomiasis, ascariasis, filariasis, onchocerciasis, Schis or/and prevent non-pathogenic inflammatory caused debili tosomiasis, and trichuriasis, (vi) human papillomavirus, (vii) tating human medical conditions arising, for example, from influenza, and (viii) mother to child transmission of chlamy chronic fibrinous, granulomatous, pseudomembranous, dia, gonorrhea, hepatitis, HIV, human papillomavirus, and purulent, serous, or/and ulcerative inflammation. tuberculosis. 0255. The compositions provided by the products of the 0250. The products of the invention may be used to treat invention, including or/and along with compositions having or/and prevent virally caused debilitating human medical the formulations of the medicinal drug of types I and II, may conditions arising, for example, from: (i) double-stranded be used as anti-pathogenic, anti-inflammatory, or/and as dis DNA viruses including caudovirales, herpesvirales, ascoviri ease preventative materials to treat, or otherwise be applied dae, adenoviridae, asfarviridae, baculoviridae, cocco to, nutrients, oils, eukaryotic products, animal food products lithoviridae, corticoviridae, fuselloviridae, guttaviridae, iri including meat and seafood, crops, eggs, flour, honey, mush doviridae, lipothrixviridae, mimiviridae, nimaviridae, rooms, seasonings, seeds, Sugar, vegetables, fruits and dry papillomaviridae, phycodnaviridae, plasmaviridae, polyo fruits, dairy products, beverage products, cereals, other food maviridae, poxyiridae, rudiviridae, tectiviridae, ampullavi products, or/and their derived products. rus, nudivirus, Salterprovirus, Sputnik Virophage, and rhizid 0256 The compositions provided by the products of the iovirus, (ii) single-stranded DNA viruses including the invention, including or/and along with compositions having bacteriophage families inoviridae and microviridae and the formulations of the medicinal drug of types I and II, may anelloviridae, circoviridae, geminiviridae, nanoviridae, and be used as (i) algaecides, algaestats, bleaches, degreasers, parvoviridae, (iii) double-stranded RNA viruses including, deodorants, deodorizers, detergents and Soaps, emulsifiers, birnaviridae, cystoviridae, hypoviridae, partitiviridae, insecticides and pesticides, sanitizers, stain removers, whit reoviridae, and totiviridae, (iv) positive-sense single-stranded eners, and disinfectants for inanimate Surfaces including RNA viruses including, nidovirales, picornavirales, tymovi asphalt, ceramic, clay, concrete, contact lens, drywall, glass, rales, astroviridae, barnaviridae, bromoviridae, caliciviridae, granite, marble, metal, plastic, salt, sand, slate, stone, and closteroviridae, flaviviridae, leviviridae, luteoviridae, nar wood, for animate Surfaces including body, face, hands, and naviridae, nodaviridae, potyviridae, tetraviridae, togaviridae, feet, for blood, and for airborne pathogens, (ii) etchants for tombusviridae, benyvirus, furovirus, hepevirus, hordeivirus, various materials including metals, and (iii) oxidizers for idaeovirus, ourmiavirus, pecluvirus, pomovirus, Sobemovi various materials including coal, gases, metals, metalloids, rus, tobamovirus, tobravirus, and umbravirus, (v) negative nonmetals, oils, paper, paper pulp, wood, and wood pulp. sense single-stranded RNA viruses including, mononegavi 0257 The compositions provided by the products of the rales, arenaviridae, bunyaviridae, orthomyxoviridae, invention, including or/and along with compositions having deltavirus, nyavirus, ophiovirus, tenuivirus, and varicosavi the formulations of the medicinal drug of types I and II, may rus, (vi) single-stranded RNA reverse-transcription viruses be used in bandages, bark, burn treatment materials, cosmetic including, retroviruses, and (vii) double-stranded DNA products, dentures, diapers, fertilizer, fibers including textiles reverse-transcription viruses including, hepadnaviridae. from animal (wool and silk), plant (cotton, flax, and jute), 0251. The products of the invention may be used to treat mineral (asbestos and glass fiber), other natural, and synthetic or/and prevent bacterially caused debilitating human medical (nylon, polyester, and acrylic, cellulose, and polymer) conditions arising, for example, from: (i) gram positive bac sources, microfibers, leather, rubber, hair products, handheld teria with no outer membrane including, actinobacteria, fir wands, mops and scrubbing products, industrial products, micutes, and tenericutes, (ii) gram negative bacteria with medicinal products, preservation and other shelf-life-increas outer membrane including, aquificae, bacteroidetes, chlamy ing products, sanitary wipes, soil, tampons, toothpaste and diae, chlorobi, deinococcus-thermus, fusobacteria, gemmati mouthwash, wound treatment materials, and other consumer monadetes, nitrospirae, proteobacteria, Spirochaetes, syner products. gistetes, and Verrucomicrobia, and (iii) acidobacteria, 0258. In addition to the previous applications, the products chloroflexi, chrysiogenetes, cyanobacteria, deferribacteres, of the invention can be used in other non-medical industrial dictyoglomi, fibrobacteres, planctomycetes, thermodesulfo and commercial applications. Furthermore, the products of bacteria, and thermotogae. the invention can be used to treat conditions other than human 0252. The products of the invention may be used to treat or non-human animal debilitating medical conditions such as or/and prevent fungal caused debilitating human medical colony collapse disorder of bees. Various changes and appli conditions arising, for example, from blastocladiomycota, cations may thus be made without departing from the true chytridiomycota, glomeromycota, microsporidia, neocalli Scope of the invention as defined in the appended claims. mastigomycota, dikarya, Zygomycota, and deuteromycota. We claim: 0253) The products of the invention may be used to treat 1. A disintegrable composition for introduction into a liq or/and prevent parasite-caused debilitating human medical uid, the composition (a) having a mass of an initial mass value conditions arising, for example, from: (i) endoparasites immediately prior to introduction into the liquid, (b) compris including the plant group of rafflesiaceae, (ii) parasitic worms ing active material comprising salt of peroxymonosulfuric including the groups ofcestodes, nematodes, and trematodes, acid, and (c) being of Such a structure that the composition (iii) ectoparasites including the plant groups of broomrape, gradually disintegrates upon introduction into the liquid for cuscuta, mistletoe, Santalum, toothwort, and wood rose, (iv) enabling particles of the composition to disperse into the US 2012/0074014 A1 Mar. 29, 2012 28 liquid so that the mass of the composition is 10% to 90% of medical condition of the person or/and to prevent the person the initial mass value 1 hour to 100 days after the composition from contracting the medical condition. is introduced into the liquid. 12. A composition comprising: 2. A composition as in claim 1 wherein the salt of peroxy a carrier; and monosulfuric acid comprises potassium hydrogen peroxy active material dispersed largely throughout the carrier monosulfate. Such that the composition is semiliquid, the active mate 3. A composition as in claim 1 wherein the active material rial comprising (a) inorganic halide or/and reaction further includes at least one of the following additional mate product of the inorganic halide and other material of the rials: inorganic halide, metal phosphate, Sulfamic acid, a non composition and (b) an oxidizing agent or/and reaction reducing organic acid, and a surfactant. product of the oxidizing agent and other material of the 4. A method comprising: composition, the oxidizing agent being reactable in combining material of the composition of claim 1 with water with the inorganic halide to generate hypohalite material of the liquid to form a further composition; and ions. administering material of the further composition to a per 13. A composition as in claim 12 wherein the active mate Son Sufficiently to treat a medical condition of the person rial further includes at least one of the following additional or/and to prevent the person from contracting the medi materials: cal condition. metal phosphate or/and reaction product of the metal phos 5. A disintegrable composition for introduction into a liq phate and other material of the composition; uid comprising water, the composition (a) having a mass of an Sulfamic acid or/and reaction product of Sulfamic acid and initial mass value immediately prior to introduction into the other material of the composition; liquid, (b) comprising active material comprising inorganic a non-reducing organic acid or/and reaction product of the halide and an oxidizing agent reactable in water with the organic acid and other material of the composition; and inorganic halide to generate hypohalite ions, and (c) being of a surfactant or/and reaction product of the Surfactant and Such a structure that the composition gradually disintegrates other material of the composition. upon introduction into the liquid for enabling particles of the 14. A method comprising administering material of the composition to disperse into the liquid so that the mass of the composition of claim 12 to a person Sufficiently to treat a composition is 10% to 90% of the initial mass value 1 hour to medical condition of the person or/and to prevent the person 100 days after the composition is introduced into the liquid. from contracting the medical condition. 6. A composition as in claim 5 wherein the active material 15. A product comprising: further includes at least one of the following additional mate a composition comprising a carrier and active material rials: metal phosphate, Sulfamic acid, a non-reducing organic dispersed largely throughout the carrier, the active mate acid, and a surfactant. rial comprising salt of peroxymonosulfuric acid or/and 7. A method comprising: reaction product of the salt of peroxymonosulfuric acid combining material of the composition of claim 5 with and other material of the composition; and material of the liquid to form a further composition; and a container containing the composition and Substantially administering material of the further composition to a per blocking transmission of visible light incident on the Son Sufficiently to treat a medical condition of the person container from outside the container. or/and to prevent the person from contracting the medi 16. A product as in claim 15 wherein the salt of peroxy cal condition. monosulfuric acid comprises potassium hydrogen peroxy 8. A composition comprising: monosulfate. a carrier, and 17. A product as in claim 15 wherein the active material active material dispersed largely throughout the carrier further includes at least one of the following additional mate Such that the composition is semiliquid, the active mate rials: rial comprising salt of peroxymonosulfuric acid or/and inorganic halide or/and reaction product of the inorganic reaction product of the salt of peroxymonosulfuric acid halide and other material of the composition; and other material of the composition. metal phosphate or/and reaction product of the metal phos 9. A composition as in claim 8 wherein the salt of peroxy phate and other material of the composition; monosulfuric acid comprises potassium hydrogen peroxy Sulfamic acid or/and reaction product of Sulfamic acid and monosulfate. other material of the composition; 10. A composition as in claim 8 wherein the active material a non-reducing organic acid or/and reaction product of the further includes at least one of the following additional mate organic acid and other material of the composition; and rials: a surfactant or/and reaction product of the Surfactant and inorganic halide or/and reaction product of the inorganic other material of the composition. halide and other material of the composition; 18. A method of manufacturing the product of claim 15, the metal phosphate or/and reaction product of the metal phos method comprising: phate and other material of the composition; providing the composition and the container; and Sulfamic acid or/and reaction product of Sulfamic acid and introducing the composition into the container. other material of the composition; 19. A method comprising administering material of the a non-reducing organic acid or/and reaction product of the composition of claim 15 to a person sufficiently to treat a organic acid and other material of the composition; and medical condition of the person or/and to prevent the person a surfactant or/and reaction product of the Surfactant and from contracting the medical condition. other material of the composition. 20. A product comprising: 11. A method comprising administering material of the a composition comprising a carrier and active material composition of claim 8 to a person Sufficiently to treat a dispersed largely throughout the carrier, the active mate US 2012/0074014 A1 Mar. 29, 2012 29

rial comprising (a) inorganic halide or/and reaction 30. A product comprising: product of the inorganic halide and other material of the a composition comprising a carrier and active material composition and (b) an oxidizing agent or/and reaction dispersed largely throughout the carrier, the active mate product of the oxidizing agent and other material of the rial comprising (a) inorganic halide or/and reaction composition, the oxidizing agent being reactable in product of the inorganic halide and other material of the water with the inorganic halide to generate hypohalite composition and (b) an oxidizing agent or/and reaction ions; and product of the oxidizing agent and other material of the a container containing the composition and Substantially composition, the oxidizing agent being reactable in blocking transmission of visible light incident on the water with the inorganic halide to generate hypohalite container from outside the container. ions; and 21. A product as in claim 20 wherein the active material a container which contains the composition and inside further includes at least one of the following additional mate which the composition is subjected to an average pres rials: Sure of more than 1 atm. metal phosphate or/and reaction product of the metal phos 31. A product as in claim 30 wherein the active material phate and other material of the composition; further includes at least one of the following additional mate Sulfamic acid or/and reaction product of Sulfamic acid and rials: other material of the composition; a non-reducing organic acid or/and reaction product of the metal phosphate or/and reaction product of the metal phos organic acid and other material of the composition; and phate and other material of the composition; a surfactant or/and reaction product of the Surfactant and Sulfamic acid or/and reaction product of Sulfamic acid and other material of the composition. other material of the composition; 22. A method of manufacturing the product of claim 20, the a non-reducing organic acid or/and reaction product of the method comprising: organic acid and other material of the composition; and providing the composition and the container, and a surfactant or/and reaction product of the Surfactant and introducing the composition into the container. other material of the composition. 23. A method comprising administering material of the 32. A product as in claim 30 wherein the average pressure composition of claim 20 to a person Sufficiently to treat a inside the container is at least 2 atm. medical condition of the person or/and to prevent the person 33. A method of manufacturing the product of claim 30, the from contracting the medical condition. method comprising: 24. A product comprising: providing the composition and the container; and a composition comprising a carrier and active material introducing the composition into the container. dispersed largely throughout the carrier, the active mate 34. A method comprising administering material of the rial comprising salt of peroxymonosulfuric acid or/and composition of claim 30 to a person sufficiently to treat a reaction product of the salt of peroxymonosulfuric acid medical condition of the person or/and to prevent the person and other material of the composition; and from contracting the medical condition. a container which contains the composition and inside 35. A product comprising: which the composition is subjected to an average pres a composition comprising a carrier and active material Sure of more than 1 atm. dispersed largely throughout the carrier, the active mate 25. A product as in claim 24 wherein the salt of peroxy rial comprising salt of peroxymonosulfuric acid or/and monosulfuric acid comprises potassium hydrogen peroxy reaction product of the salt of peroxymonosulfuric acid monosulfate. and other material of the composition; 26. A product as in claim 24 wherein the active material a container which contains the composition; and further includes at least one of the following additional mate a dispenser hermetically attached to the container for con rials: trollably dispensing material of the composition from inorganic halide or/and reaction product of the inorganic the container, the dispenser Substantially preventing halide and other material of the composition; material outside the container and the dispenser from metal phosphate or/and reaction product of the metal phos entering the container through the dispenser. phate and other material of the composition; Sulfamic acid or/and reaction product of Sulfamic acid and 36. A product as in claim 35 wherein the salt of peroxy other material of the composition; monosulfuric acid comprises potassium hydrogen peroxy a non-reducing organic acid or/and reaction product of the monosulfate. organic acid and other material of the composition; and 37. A product as in claim 25 wherein the active material a surfactant or/and reaction product of the Surfactant and further includes at least one of the following additional mate other material of the composition. rials: 27. A product as in claim 24 wherein the average pressure inorganic halide or/and reaction product of the inorganic inside the container is at least 2 atm. halide and other material of the composition; 28. A method of manufacturing the product of claim 24, the metal phosphate or/and reaction product of the metal phos method comprising: phate and other material of the composition; providing the composition and the container, and Sulfamic acid or/and reaction product of Sulfamic acid and introducing the composition into the container. other material of the composition; 29. A method comprising administering material of the a non-reducing organic acid or/and reaction product of the composition of claim 24 to a person Sufficiently to treat a organic acid and other material of the composition; and medical condition of the person or/and to prevent the person a surfactant or/and reaction product of the Surfactant and from contracting the medical condition. other material of the composition. US 2012/0074014 A1 Mar. 29, 2012 30

38. A method of manufacturing the product of claim35, the 46. A product as in claim 44 wherein the active material method comprising: further includes at least one of the following additional mate providing the composition, the container, and the dis rials: inorganic halide, metal phosphate, Sulfamic acid, a non penser; and reducing organic acid, and a surfactant. assembling the container, the dispenser, and the composi 47. A method of manufacturing the product of claim 44, the tion into a structure by a procedure that entails introduc method comprising: ing the composition into the container. providing the carrier, the composition, and the containers; 39. A method comprising administering material of the and composition of claim 35 to a person sufficiently to treat a assembling the containers, the carrier, and the composition medical condition of the person or/and to prevent the person into a structure by a procedure that entails introducing from contracting the medical condition. the carrier and the composition respectively into the first 40. A product comprising: and second containers. a composition comprising a carrier and active material 48. A method comprising administering material of the dispersed largely throughout the carrier, the active mate further composition of claim 44 to a person sufficiently to rial comprising (a) inorganic halide or/and reaction treat a medical condition of the person or/and to prevent the product of the inorganic halide and other material of the person from contracting the medical condition. composition and (b) an oxidizing agent or/and reaction 49. A product comprising: product of the oxidizing agent and other material of the a liquid carrier comprising water, composition, the oxidizing agent being reactable in a first container containing the carrier; water with the inorganic halide to generate hypohalite a primary composition comprising active material com ions; prising inorganic halide and an oxidizing agent reactable a container which contains the composition; and a dispenser hermetically attached to the container for con in the water with the inorganic halide to generate hypo trollably dispensing material of the composition from halite ions; and the container, the dispenser Substantially preventing a second container containing the primary composition; material outside the container and the dispenser from and entering the container through the dispenser. a combining element attached to or integral with at least 41. A product as in claim 40 wherein the active material one of the containers, or Suitable for attachment to at further includes at least one of the following additional mate least one of the containers, for enabling matter of the rials: primary composition and matter of the carrier to be metal phosphate or/and reaction product of the metal phos controllably combined to form a further composition. phate and other material of the composition; 50. A product as in claim 49 wherein the active material Sulfamic acid or/and reaction product of Sulfamic acid and further includes at least one of the following additional mate other material of the composition; rials: metal phosphate, Sulfamic acid, a non-reducing organic a non-reducing organic acid or/and reaction product of the acid, and a surfactant. organic acid and other material of the composition; and 51. A method of manufacturing the product of claim 49, the a surfactant or/and reaction product of the Surfactant and method comprising: other material of the composition. providing the carrier, the composition, and the containers; 42. A method of manufacturing the product of claim 40, the and method comprising: assembling the containers, the carrier, and the composition providing the composition, the container, and the dis by a procedure that entails introducing the carrier and penser; and the composition respectively into the first and second assembling the container, the dispenser, and the composi containers. tion into a structure by a procedure that entails introduc 52. A method comprising administering material of the ing the composition into the container. further composition of claim 49 to a person sufficiently to 43. A method comprising administering material of the treat a medical condition of the person or/and to prevent the composition of claim 40 to a person Sufficiently to treat a person from contracting the medical condition. medical condition of the person or/and to prevent the person 53. A particle-containing composition comprising a plural from contracting the medical condition. ity of solid particles comprised of support material and active 44. A product comprising: material comprising salt of peroxymonosulfuric acid, the salt a liquid carrier; of peroxymonosulfuric acid being present in the particles at a first container containing the liquid carrier, an average mass percentage of no more than 10%. a primary composition comprising active material com 54. A composition as in claim 53 wherein the salt of per prising salt of peroxymonosulfuric acid; oxymonosulfuric acid comprises potassium hydrogen per a second container containing the primary composition; oxymonosulfate. and 55. A composition as in claim 53 wherein the particles are a combining element attached to or integral with at least of an average diameter of no more than 500 Lum. one of the containers, or Suitable for attachment to at 56. A composition as in claim 53 wherein the active mate least one of the containers, for enabling matter of the rial includes at least one of the following additional materials: primary composition and matter of the carrier to be inorganic halide, metal phosphate, Sulfamic acid, a non-re controllably combined to form a further composition. ducing organic acid, and a surfactant. 45. A product as in claim 44 wherein the salt of peroxy 57. A method of preparing the composition of claim 53, the monosulfuric acid comprises potassium hydrogen peroxy method comprising combining the active material and the monosulfate. Support material to form the particles. US 2012/0074014 A1 Mar. 29, 2012 31

58. A method comprising: 65. A composition as in claim 63 wherein the salt of per combining a liquid carrier and a composition as in claim 53 oxymonosulfuric acid comprises potassium hydrogen per to produce a further composition in which further active oxymonosulfate. material is dispersed largely throughout the carrier, the 66. A composition as in claim 63 wherein the active mate further active material comprising the salt of peroxy rial further includes at least one of the following additional materials: monosulfuric acid or/and reaction product of the salt of inorganic halide or/and reaction product of the inorganic peroxymonosulfuric acid and other material of the fur halide and other material of the composition; ther composition: and metal phosphate or/and reaction product of the metal phos administering material of the further composition to a per phate and other material of the composition; Son Sufficiently to treat a medical condition of the person Sulfamic acid or/and reaction product of Sulfamic acid and or/and to prevent the person from contracting the medi other material of the composition; cal condition. a non-reducing organic acid or/and reaction product of the 59. A particle-containing composition comprising a plural organic acid and other material of the composition; and ity of solid particles comprised of support material and active a surfactant or/and reaction product of the Surfactant and material comprising inorganic halide and an oxidizing agent other material of the composition. reactable in water with the inorganic halide to generate hypo 67. A method comprising administering material of the halite ions, the oxidizing agent being present in the particles composition of claim 63 to a person sufficiently to treat a at an average mass percentage of no more than 10%. medical condition of the person or/and to prevent the person from contracting the medical condition. 60. A composition as in claim 59 wherein the particles are 68. A composition comprising: of an average diameter of no more than 500 Lum. a liquid carrier comprising water, 61. A composition as in claim 59 wherein the active mate active material dispersed largely throughout the carrier, the rial include at least one of the following additional materials: active material comprising (a) inorganic halide or/and metal phosphate, Sulfamic acid, a non-reducing organic acid, reaction product of the inorganic halide and other mate and a surfactant. rial of the composition and (b) an oxidizing agent or/and 62. A method comprising: reaction product of the oxidizing agent and other mate combining a liquid carrier and a composition as in claim 59 rial of the composition, the oxidizing agent being to produce a further composition in which further active reactable in water with the inorganic halide to generate material is dispersed largely throughout the carrier, the hypohalite ions and having active oxygen consisting of further active material comprising the salt of peroxy chemically readily transferable oxygen atoms; and monosulfuric acid or/and reaction product of the salt of an inhibitor dispersed largely throughout the carrier for peroxymonosulfuric acid and other material of the fur inhibiting loss of active oxygen from the composition. ther composition; and 69. A composition as in claim 68 wherein the inhibitor administering material of the further composition to a per causes the loss of active oxygen from the claimed composi Son Sufficiently to treat a medical condition of the person tion to be at least 10% lower as a function of time than what or/and to prevent the person from contracting the medi would arise in a comparative composition lacking the inhibi cal condition. tor but otherwise constituted the same as the claimed compo 63. A composition comprising: sition up to a point at which the comparative composition has lost 50% of its active oxygen. a liquid carrier; 70. A composition as in claim 68 wherein the active mate active material dispersed largely throughout the carrier, the rial further includes at least one of the following additional active material comprising salt of peroxymonosulfuric materials: acid or/and reaction product of the salt of peroxymono metal phosphate or/and reaction product of the metal phos Sulfuric acid and other material of the composition, the phate and other material of the composition; salt of peroxymonosulfate having active oxygen consist Sulfamic acid or/and reaction product of Sulfamic acid and ing of chemically readily transferable oxygen atoms; other material of the composition; and a non-reducing organic acid or/and reaction product of the an inhibitor dispersed largely throughout the carrier for organic acid and other material of the composition; and inhibiting loss of active oxygen from the composition. a surfactant or/and reaction product of the Surfactant and 64. A composition as in claim 63 wherein the inhibitor other material of the composition. causes the loss of active oxygen from the claimed composi 71. A method comprising administering material of the tion to be at least 10% lower as a function of time than what composition of claim 68 to a person sufficiently to treat a would arise in a comparative composition lacking the inhibi medical condition of the person or/and to prevent the person tor but otherwise constituted the same as the claimed compo from contracting the medical condition. sition up to a point at which the comparative composition has lost 50% of its active oxygen. c c c c c